

TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

09/869079

INTERNATIONAL APPLICATION NO.

INTERNATIONAL FILING DATE

PCT/GB99/04311 ✓

December 17, 1999 ✓

PRIORITY DATE CLAIMED

December 22, 1998 ✓

TITLE OF INVENTION

HUMAN AKT-3 ✓

APPLICANT(S) FOR DO/EO/US:

MASURE et al. → STEFAN LEO JOZEF

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
- a. ☒ is transmitted herewith (required only if not transmitted by the International Bureau).
- b. ☐ has been transmitted by the International Bureau.
- c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
- a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
- b. ☐ have been transmitted by the International Bureau.
- c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
- d. ☐ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ A translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☒ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A FIRST preliminary amendment with version to show changes made.
- ☐ A SECOND or SUBSEQUENT preliminary amendment.
14. ☒ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☒ Other items or information: Copy of the International Search Report; Sequence Disk; Sequence Listing; Associate Power of Attorney; Verified Statement Under 37 CFR 1.821(f).

U.S. APPLICATION NO. (if known, see 37 CFR 1.5)

INTERNATIONAL APPLICATION NO.

ATTORNEY'S DOCKET NUMBER

PCT/GB99/04311

JAB-1458

09/869079

17. ☒ The following fees are submitted:

BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):

Neither international preliminary examination fee (37 CFR 1.482)
nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO
and International Search Report not prepared by the EPO or JPO..... \$1070.00

International preliminary examination fee (37 CFR 1.482) not paid to
USPTO but International Search Report prepared by the EPO or JPO.....\$930.00

International preliminary examination fee (37 CFR 1.482) not paid to
USPTO but international search fee (37 CFR 1.455(a)(2)) paid to USPTO..... \$790.00

International preliminary examination fee (37 CFR 1.482) paid to
USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4)..... \$720.00

International preliminary examination fee (37 CFR 1.482) paid to
USPTO and all claims satisfied provisions of PCT Article 33(1)-(4)..... \$98.00

ENTER APPROPRIATE BASIC FEE AMOUNT =

\$ 930.00

Surcharge of \$130.00 for furnishing the oath or declaration later than
months from the earliest claimed priority date (37 CFR 1.492(e)). ☐ 20 ☐ 30 \$

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	
Total claims	35 - 20 =	15	x \$18.00	\$ 270.00
Independent claims	24 - 3 =	21	x \$80.00	\$ 1680.00
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$270.00	\$ 0

TOTAL OF ABOVE CALCULATIONS =

\$

Reduction of 1/2 for filing by small entity, if applicable. A Small Entity Statement
must also be filed (Note 37 CFR 1.9, 1.27, 1.28). + \$ 0

SUBTOTAL =

\$ 2880.00

Processing fee of \$130.00 for furnishing the English translation later than ☐ 20 ☐ 30 \$ 0
months from the earliest claimed priority date (37 CFR 1.492(f)).

TOTAL NATIONAL FEE =

\$ 2880.00

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be
accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property + \$ 40.00

TOTAL FEES ENCLOSED =

\$ 2920.00

Amount to be
refunded: \$
charged: \$ 2920.00

a. ☐ A check in the amount of \$_____ to cover the above fees is enclosed.

b. ☒ Please charge my Deposit Account No. 10-0750/JAB-1458/MHM in the amount of \$2920.00 to cover the above fee
A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any
overpayment to Deposit Account No. 10-0750/JAB-1458/MHM. A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or
(b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Philip S. Johnson, Esq.
Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
USA

Signature

Myra McCormack
Reg. No. 36,602
Attorney for Applicants
June 20, 2001

Docket No. JAB-1458

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Masure, et al.

Serial No. : unknown

Art Unit: unknown

Filed : herewith

Examiner: unknown

For : Human AKT-3

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on

June 20, 2001

(Date)

Myra H. McCormack

Name of applicant, assignee, or Registered Representative

Myra McCormack
(Signature)

June 20, 2001

(Date of Signature)

Commissioner for Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Dear Sir:

Prior to the examination of the above-referenced application, kindly amend the application as follows:

IN THE SPECIFICATION

Before the first line of the specification and after the title kindly insert the following paragraph:
--This application is a national stage filing of International Publication Number WO/00/37613 filed December 17, 1999 which claims priority from Great Britain Patent Application No. 9828375.7 filed December 22, 1998 and entitled "Human AKT-3"--.

Kindly insert the paper copy of the sequence listing provided herewith as pages 45-51 into the specification. Kindly renumber the pages of claims beginning at page 52.

IN THE CLAIMS

Kindly cancel claims 13-15, 22, 28, 29, 36, and 37

Kindly amend the following claims:

2. (Amended) A nucleic acid molecule according to claim 1 which is a DNA molecule.
3. (Amended) A nucleic acid molecule according to claim 1 comprising the nucleotide sequence illustrated in SEQ ID No. 1.
4. (Amended) A nucleic acid molecule according to claim 1 comprising the nucleotide sequence in SEQ ID No. 2.
5. (Amended) An antisense molecule capable of hybridising to the molecule according to claim 1 under high stringency conditions.
7. (Amended) A human Akt-3 protein or a functional equivalent, derivative or bioprecursor thereof encoded by a nucleic acid molecule according to any of claim 1.
9. (Amended) An expression vector comprising a nucleic acid molecule according to claim 2.
11. (Amended) An expression vector according to claim 9 comprising a sequence encoding a reporter molecule.
12. (Amended) A nucleic acid molecule according to any of claim 1 for use as a medicament.
16. (Amended) A pharmaceutical composition comprising a nucleic acid molecule according to claim 1 or a human Akt-3 protein according to any of claim 6 together with a pharmaceutically acceptable carrier diluent or excipient therefor.

17. (Amended) A host cell or organism, transformed or transfected with an expression vector according to claim 9.

18. (Amended) A transgenic cell, tissue or organism comprising a transgene capable of expressing a human Akt-3 protein according to claim 6.

19. (Amended) A human Akt-3 protein expressed from the cell or organism according to claim 17.

20. (Amended) An antibody capable of binding to a human Akt-3 protein or an epitope thereof according to claim 6.

23. (Amended) A medicament comprising the antibody of claim 20.

24. (Amended) A kit for detecting human Akt-3 protein in a sample which protein comprises a sequence according to any of claims 6, said kit comprising an antibody according to claim 20.

25. (Amended) A method of identifying compounds which selectively inhibit human Akt-3 protein mediated promotion of cell survival said method comprising:

- i) providing a cell transformed with an expression vector activating the Akt-3 pathway that survives in the presence or absence of a survival factor compared to a control cell which has not been transformed with said vector and will die in the absence of said survival factor, and
- ii) contacting each of said cells with a test compound following the removal of said cells from said survival factor, wherein death of said transformed cell is indicative of selective inhibition of said compound on the survival promoting human Akt-3 pathway.

26. (Amended) A method of identifying compounds which selectively inhibit human Akt-3 protein mediated promotion of cell survival, said method comprising:

- i) providing a cell transformed with an expression vector activating the Akt-3 pathway in addition to a control cell which has not been transformed with said vector,
- ii) contacting each of said cells with a death inducing agent, whereby death of said control cell and survival of said transformed cell is indicative of the survival promoting activity of the activated Akt-3 pathway, and
- iii) contacting said transformed cell with a test compound, wherein death of said cell is indicative of selective inhibition of said compound on the survival promoting human Akt-3 pathway.

27. (Amended) A compound identifiable according to the method of claim 25.

30. (Amended) A method of identifying agents which influence the activity of a human Akt-3 protein according to claim 6, said method comprising contacting said human Akt-3 protein with a substrate therefor in the presence of a test compound and a phosphate source, and monitoring for phosphorylation of said substrate.

33. (Amended) A method of identifying agents which influence the activity of a human Akt-3 protein according to claim 6, said method comprising contacting a phospholipid or a surrogate or functional equivalent thereof, with a PH domain of a human Akt-3 protein according to claim 6 in the presence of an agent to be tested and monitoring for binding of said phospholipid, surrogate or functional equivalent thereof with said PH domain of said Akt-3 protein.

35. (Amended) An agent identifiable according to the method of claim 33.

38. (Amended) A method of treating diseases associated with human Akt-3 activity said method

comprising administering to an individual suffering from said disease a compound that inhibits the function and/or expression of a human Akt-3 protein according to claim 6, in a sufficient concentration to reduce the symptoms of said disease.

39. (Amended) A method according to claim 38 wherein said compound is any of an antisense molecule according to claim 5, an antibody according to claim 21, a compound according to claim 27 or an agent according to claim 35.

41. (Amended) A method of identifying a compound which modulates Akt-3 kinase activity, comprising:

- a) contacting said Akt-3 with a substrate thereof in the presence of a radiolabelled phosphate source, and the compound to be tested,
- b) stopping the reaction by the addition of kinase inhibitor in the presence of SPA beads, and
- c) monitoring the signal from said beads compared to a control which has not been contacted with said compound.


Kindly add the following claim:

43. (New) A compound identifiable according to the method of claim 26.

REMARKS

Claims 13-15, 22, 28, 29, 36, and 37 have been canceled. The specification has been amended to incorporate the priority information for this Application. The claims have been amended solely for the purpose of removing multiple dependencies and aligning the claims to a U.S. acceptable claim format. A substitute sequence listing has been provided along with a Computer Readable Form of the Sequence Listing. The undersigned hereby states that the Paper Copy and the Computer Readable Form are identical. No new matter has been added by these amendments. Favorable consideration of the remarks provided below is respectfully requested. Should the Examiner have any questions he is invited to contact the undersigned at the telephone number provided below.

Respectfully submitted,


Myra H. McCormack
Attorney for Applicants
Reg. No. 36,602

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-6932
Dated: June 20, 2001

VERSION TO SHOW CHANGES MADE**IN THE CLAIMS**

Claims 13-15, 22, 28, 29, 36, and 37 have been canceled and claim 43 has been added.

The following claims have been amended as follows:

2. (Amended) A nucleic acid molecule according to claim 1 which is a DNA molecule[, and preferably cDNA].
3. (Amended) A nucleic acid molecule according to claim 1 [or 2] comprising the nucleotide sequence illustrated in SEQ ID No. 1.
4. (Amended) A nucleic acid molecule according to claim 1 [or 2] comprising the nucleotide sequence in SEQ ID No. 2.
5. (Amended) An antisense molecule capable of hybridising to the molecule according to [any of] claim[s] 1 [to 4] under high stringency conditions.
7. (Amended) A human Akt-3 protein or a functional equivalent, derivative or bioprecursor thereof encoded by a nucleic acid molecule according to any of claim[s] 1 [to 4].
9. (Amended) An expression vector comprising a nucleic acid molecule according to claim 2 [or 3].
11. (Amended) An expression vector according to claim 9 [or 10] comprising a sequence encoding a reporter molecule.
12. (Amended) A nucleic acid molecule according to any of claim[s] 1 [to 5] for use as a medicament.
16. (Amended) A pharmaceutical composition comprising a nucleic acid molecule according to [any of] claim[s] 1 [to 5] or a human Akt-3 protein according to any of claim[s] 6 [to 8] together with a pharmaceutically acceptable carrier diluent or excipient therefor.

17. (Amended) A host cell or organism, transformed or transfected with an expression vector according to [any of] claim[s] 9 [to 11].
18. (Amended) A transgenic cell, tissue or organism comprising a transgene capable of expressing a human Akt-3 protein according to [any of] claim[s] 6 [to 8].
19. (Amended) A human Akt-3 protein expressed from the cell or organism according to claim 17 [or 18].
20. (Amended) An antibody capable of binding to a human Akt-3 protein or an epitope thereof according to [any of] claim[s] 6 [to 8].
23. (Amended) [Use of an] A medicament comprising the antibody according to claim 20 [or 21 in the preparation of a medicament for treating cancer, or other diseases or conditions associated with human Akt-3 protein expression].
24. (Amended) A kit for detecting human Akt-3 protein in a sample which protein comprises a sequence according to any of claims 6 [to 8], said kit comprising an antibody according to claim 20 [or 21 and means for contacting said antibody with said sample].
25. (Amended) A method of identifying compounds which selectively inhibit human Akt-3 protein mediated promotion of cell survival said method comprising:
- i) providing a cell transformed with an expression vector activating the Akt-3 pathway that survives in the presence or absence of a survival factor compared to a control cell which has not been transformed with said vector and will die in the absence of said survival factor, and
 - ii) contacting each of said cells with a test compound following the removal of said cells from said survival factor, wherein death of said transformed cell is indicative of selective inhibition of said compound on the survival promoting human Akt-3 pathway.

26. (Amended) A method of identifying compounds which selectively inhibit human Akt-3 protein mediated promotion of cell survival, said method comprising:
- i) providing a cell transformed with an expression vector activating the Akt-3 pathway in addition to a control cell which has not been transformed with said vector,
 - ii) contacting each of said cells with a death inducing agent, whereby death of said control cell and survival of said transformed cell is indicative of the survival promoting activity of the activated Akt-3 pathway, and
 - iii) contacting said transformed cell with a test compound, wherein death of said cell is indicative of selective inhibition of said compound on the survival promoting human Akt-3 pathway.
27. (Amended) A compound identifiable according to the method of claim[s] 25 [or 26].
30. (Amended) A method of identifying agents which influence the activity of a human Akt-3 protein according to [any of] claim[s] 6 [to 8], said method comprising contacting said human Akt-3 protein with a substrate therefor in the presence of a test compound and a phosphate source, and monitoring for [any]phosphorylation of said substrate.
33. (Amended) A method of identifying agents which influence the activity of a human Akt-3 protein according to [any of] claim[s] 6 [to 8], said method comprising contacting a phospholipid or a surrogate or functional equivalent thereof, with a PH domain of a human Akt-3 protein according to [any of] claim[s] 6 [to 8] in the presence of an agent to be tested and monitoring for [any] binding of said phospholipid, surrogate or functional equivalent thereof with said PH domain of said Akt-3 protein.
35. (Amended) An agent identifiable according to the method of claim 33 [or 34].

38. (Amended) A method of treating diseases associated with human Akt-3 activity said method comprising administering to an individual suffering from said disease a compound that inhibits the function and/or expression of a human Akt-3 protein according to [any of] claim[s] 6 [to 8], in a sufficient concentration to reduce the symptoms of said disease.

39. (Amended) A method according to claim 38 wherein said compound is any of an antisense molecule according to claim 5, an antibody according to claim 21 [or 22], a compound according to claim 27 or an agent according to claim 35.

41. (Amended) A method of identifying a compound which modulates Akt-3 kinase activity, comprising:

- a) contacting said Akt-3 with a substrate thereof in the presence of a radiolabelled phosphate source, and the compound to be tested,
- b) stopping the reaction by the addition of kinase inhibitor in the presence of SPA beads, and
- c) monitoring the signal from said beads compared to a control which has not been contacted with said compound.

42. (Amended) A method of identifying a compound which modulates Akt-3 activity, comprising:

- a) contacting said Akt-3 with a substrate thereof in the presence of a radiolabelled phosphate source, and the compound to be tested,
- b) stopping the reaction,
- c) filtering the reaction mixture through phosphocellulose cation exchange paper, and
- d) monitoring the signal from said filter paper compared to a control which has not been contacted with said compound.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: MASURE et al.
For: HUMAN AKT-3
Filed: June 20, 2001
Serial No: TBD

VERIFIED STATEMENT UNDER 37 CFR §1.821(f)

I hereby verify that the computer readable diskette enclosed herewith includes the same information as provided in the Sequence Listing of the subject application, and that this statement is made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that willful false statements may jeopardize the validity of the application or any patent issued thereon.


Myra H. McCormack
Reg. No. 36,602

DATE: June 20, 2001



13 Rec'd PCT/PTO 15 APR 2002

09/869079

SEQUENCE LISTING

<110> Masure, Stefan
Richardson, Alan

<120> Human AKT-3

<130> 51869/001

<140> PCT/GB99/04311

<141> 1999-12-17

<150> GB 9828375.7

<151> 1998-12-22

<160> 3

<170> PatentIn Ver. 2.0

<210> 1

<211> 1547

<212> DNA

<213> Homo sapiens

<400> 1

gggagtcacg atgagcgatg ttaccattgt gaaagaaggt tgggttcaga agaggggaga 60
atatataaaa aactggaggc caagatactt ccttttgaag acagatggct cattcatagg 120
atataaagag aaacctcaag atgtggattt accttatccc ctcaacaact ttccagtggc 180
aaaatgccag ttaatgaaaa cagaacgacc aaagccaaac acatttataa tcagatgtct 240

ccagtggact actgttatag agagaacatt tcatgtagat actccagagg aaaggaaga 300
 atggacagaa gctatccagg ctgtagcaga cagactgcag aggcaagaag aggagagaat 360
 gaattgtagt ccaacttcac aaattgataa tataggagag gaagagatgg atgcctctac 420
 aacccatcat aaaagaaaga caatgaatga ttttgactat ttgaaactac taggtaaagg 480
 cacttttggg aaagtatttt tggttcgaga gaaggcaagt gaaaaaact atgctatgaa 540
 gattctgaag aaagaagtca ttattgcaaa ggatgaagtgc gcacacactc taactgaaag 600
 cagagtatta aagaacacta gacatccctt ttttaacatcc ttgaaatatt ccttccagac 660
 aaaagaccgt ttgtgttttg tgatggaata tgtaaatggg ggcgagctgt ttttccattt 720
 gtcgagagag cgggtgttct ctgaggaccg cacacgttct tatggtgcag aaattgtctc 780
 tgcttggac tatctacatt ccggaagat tegtgtaccgt gatctcaagt tggagaatct 840
 aatgctggac aaagatggcc acataaaaaat tacagatttt ggactttgca aagaagggat 900
 cacagatgca gccaccatga agacattctg tggcactcca gaatatctgg caccagaggt 960
 gttagaagat aatgactatg gccgagcagt agactggtgg ggcctagggg ttgtcatgta 1020
 tgaaatgatg tgtgggaggt tacctttcta caaccaggac catgagaaac tttttgaatt 1080
 aatattaatg gaagacatta aatttctctg aacactctct tcagatgcaa aatcattgct 1140
 ttcagggctc ttgataaagg atccaaaata acgccttggt ggaggaccag atgatgcaaa 1200
 agaaattatg agacacagtt tcttctctgg agtaaaactgg caagatgtat atgataaaaa 1260
 gcttgtacct ccttttaaac ctcaagtaac atctgagaca gatactagat attttgatga 1320
 agaatttaca gctcagacta ttacaataac accacctgaa aaatatgatg aggatgggat 1380
 ggactgcatg gacaatgaga ggccggccga tttccctcaa ttttctact ctgcaagtgg 1440
 acgagaataa gtctctttca ttctgctact tcaactgtcat cttcaattta ttactgaaaa 1500
 tgattcctgg acatcaccag tcctagctct tacacatagc aggggca 1547

<210> 2

<211> 1436

<212> DNA

<213> Homo sapiens

<400> 2

atgagcgaatg ttaccattgt gaaagaaggt tgggttcaga agaggggaga atatataaaa 60
aactggaggc caagatactt ccttttgaag acagatggct cattcatagg atataaagag 120
aaacctcaag atgtggattt accttatccc ctcaacaact ttctagtggc aaaatgccag 180
ttaatgaaaa cagaacgacc aaagccaaac acatttataa tcagatgtct ccagtggact 240
actgttatag agagaacatt tcatgtagat actccagagg aaaggaaga atggacagaa 300
gctatccagg ctgtagcaga cagactgcag aggcaagaag aggagagaat gaattgtagt 360
ccaacttcac aaattgataa tataggagag gaagagatgg atgcctctac aacctcatcat 420
aaaagaaaga caatgaatga ttttgactat ttgaaactac taggtaaagg cacttttggg 480
aaagttattt tgggttcaga gaaggcaagt ggaaaatact atgctatgaa gattctgaag 540
aaagaagtca ttattgcaaa ggaatgaagt gcacacactc taactgaaag cagagtatta 600
aagaacacta gacatccctt ttttaacatc ttgaaatatt ccttcagac aaaagaccgt 660
ttgtgtttt tgatggaata tgtaaatggg ggcgagctgt ttttccattt gtcgagagag 720
cgggtgttct ctgaggaccg cacacgtttc tatgggtcag aaattgtctc tccttggac 780
tatctacatt ccggaagat tgtgtaccgt gatctcaagt tggagaatct aatgctggac 840
aaagatggcc acataaaaaat tacagatttt ggactttgca aagaagggat cacagatgca 900
gccaccatga agacattctg tggcactcca gaatatctgg caccagaggt gttagaagat 960
aatgactatg gccgagcagt agactggtgg ggcctagggg ttgtcatgta tgaatgatg 1020
tgtgggaggt tacctttcta caaccaggac catgagaaac tttttgaatt aatattaatg 1080
gaagacatta aatttctctg aacactctct tcagatgcaa aatcatttgt ttcagggtctc 1140
ttgataaagg atccaaataa acgccttggg ggaggaccag atgatgcaa agaaattatg 1200
agacacagtt tcttctctgg agtaaaactg caagatgtat atgataaaaa gcttgtacct 1260
ccttttaaac ctcaagtaac atctgagaca gatactagat attttgatga agaatttaca 1320
gctcagacta ttacaataac accacctgaa aaatatgatg aggatggatg ggactgcagt 1380
gacaatgaga ggcgcgccga tttccctcaa ttttctact ctgcaagtga acgaga 1436

<210> 3

<211> 479

<212> PRT

<213> Homo sapiens

<400> 3

Met Ser Asp Val Thr Ile Val Lys Glu Gly Trp Val Gln Lys Arg Gly

1 5 10 15

Glu Tyr Ile Lys Asn Trp Arg Pro Arg Tyr Phe Leu Leu Lys Thr Asp

20 25 30

Gly Ser Phe Ile Gly Tyr Lys Glu Lys Pro Gln Asp Val Asp Leu Pro

35 40 45

Tyr Pro Leu Asn Asn Phe Ser Val Ala Lys Cys Gln Leu Met Lys Thr

50 55 60

Glu Arg Pro Lys Pro Asn Thr Phe Ile Ile Arg Cys Leu Gln Trp Thr

65 70 75 80

Thr Val Ile Glu Arg Thr Phe His Val Asp Thr Pro Glu Glu Arg Glu

85 90 95

Glu Trp Thr Glu Ala Ile Gln Ala Val Ala Asp Arg Leu Gln Arg Gln

100 105 110

Glu Glu Glu Arg Met Asn Cys Ser Pro Thr Ser Gln Ile Asp Asn Ile

115 120 125

Gly Glu Glu Glu Met Asp Ala Ser Thr Thr His His Lys Arg Lys Thr

130

135

140

Met Asn Asp Phe Asp Tyr Leu Lys Leu Leu Gly Lys Gly Thr Phe Gly

145

150

155

160

Lys Val Ile Leu Val Arg Glu Lys Ala Ser Gly Lys Tyr Tyr Ala Met

165

170

175

Lys Ile Leu Lys Lys Glu Val Ile Ile Ala Lys Asp Glu Val Ala His

180

185

190

Thr Leu Thr Glu Ser Arg Val Leu Lys Asn Thr Arg His Pro Phe Leu

195

200

205

Thr Ser Leu Lys Tyr Ser Phe Gln Thr Lys Asp Arg Leu Cys Phe Val

210

215

220

Met Glu Tyr Val Asn Gly Gly Glu Leu Phe Phe His Leu Ser Arg Glu

225

230

235

240

Arg Val Phe Ser Glu Asp Arg Thr Arg Phe Tyr Gly Ala Glu Ile Val

245

250

255

Ser Ala Leu Asp Tyr Leu His Ser Gly Lys Ile Val Tyr Arg Asp Leu

260

265

270

Lys Leu Glu Asn Leu Met Leu Asp Lys Asp Gly His Ile Lys Ile Thr

275

280

285

Asp Phe Gly Leu Cys Lys Glu Gly Ile Thr Asp Ala Ala Thr Met Lys

290

295

300

Thr Phe Cys Gly Thr Pro Glu Tyr Leu Ala Pro Glu Val Leu Glu Asp

305

310

315

320

Asn Asp Tyr Gly Arg Ala Val Asp Trp Trp Gly Leu Gly Val Val Met

325

330

335

Tyr Glu Met Met Cys Gly Arg Leu Pro Phe Tyr Asn Gln Asp His Glu

340

345

350

Lys Leu Phe Glu Leu Ile Leu Met Glu Asp Ile Lys Phe Pro Arg Thr

355

360

365

Leu Ser Ser Asp Ala Lys Ser Leu Leu Ser Gly Leu Leu Ile Lys Asp

370

375

380

Pro Asn Lys Arg Leu Gly Gly Gly Pro Asp Asp Ala Lys Glu Ile Met

385

390

395

400

Arg His Ser Phe Phe Ser Gly Val Asn Trp Gln Asp Val Tyr Asp Lys

405

410

415

Lys Leu Val Pro Pro Phe Lys Pro Gln Val Thr Ser Glu Thr Asp Thr

420

425

430

Arg Tyr Phe Asp Glu Glu Phe Thr Ala Gln Thr Ile Thr Ile Thr Pro

8/PRTS

-1-

09/869079
JAB-1458

JC18 Rec'd PCT/PTO 2 0 JUN 2001

HUMAN AKT-3

FIELD OF THE INVENTION

- 5 The present invention is concerned with cloning and expression of a new human serine/threonine kinase termed "Akt-3" and, in particular, with nucleic acid molecules encoding the Akt-3 protein, the protein itself and compounds which can be used to inhibit cell
10 survival.

BACKGROUND OF THE INVENTION

- 15 A characteristic feature of many cancer cells is their ability to grow independently of adhesion. In contrast, when untransformed endothelial cells are prevented from adhering to the extracellular matrix (ECM), they undergo apoptosis (Frisch & Francis, 1994; Meredith et al, 1993). The process by which normally
20 adherent cells are triggered to undergo apoptosis when they are unable to adhere to ECM has been termed "anoikis" (Frisch & Ruoslahti, 1997) and is an example of the effect on a cell of removal of a survival factor. Changes in signalling by adhesion molecules
25 can lead to resistance to anoikis (Frisch & Ruoslahti, 1997) and this may contribute to the mechanism whereby cancer cells that grow independently of adhesion are able to avoid anoikis.
- 30 Akt (also known as protein kinase B (PKB) or "related to A and C protein kinase" (RAC-PK)) is a serine/threonine kinase that has been implicated in regulating cell survival (Khawaja et al., 1997; Dudek et al., 1997; Kauffmann-Zeh et al., 1997; Kennedy et
35 al., 1997; Datta et al., 1997; Marte & Downward, 1997). Akt can inhibit apoptosis induced by detachment from ECM (Khawaja et al., 1997), as well as by survival factor withdrawal (Kennedy et al., 1997;

survival factor withdrawal (Kennedy et al., 1997; Ahmed et al., 1997; Dudek et al., 1997; Kauffman-Zeh et al., 1997; Philpott et al., 1997; Crowder & Freeman, 1998; Eves et al., 1998) or irradiation (Kulik et al., 1997).

Akt comprises an NH₂-terminal pleckstrin homology (PH) domain involved in lipid binding, a kinase domain and a COOH-terminal "tail". Akt is thought to be activated by recruitment to the plasma membrane and subsequent phosphorylation by two upstream kinases, PDK-1 and PDK-2 (reviewed in Coffey et al., 1998; Alessi & Cohen, 1998). The binding of 3-phosphoinositides, generated by phosphatidylinositol 3-kinase (PI 3-kinase), to the PH domain of Akt is believed to promote translocation to the plasma membrane and to facilitate phosphorylation of Akt-1 by PDK-1 at Thr³⁰⁸ (Alessi et al., 1996; Alessi et al., 1997; Stephens et al., 1998) or of Akt-2 at Thr³⁰⁹ (Meier et al., 1997). In addition to phosphorylation of Thr³⁰⁸, full activation requires phosphorylation of the COOH tail at Ser⁴⁷³ in Akt-1 (Alessi et al., 1996) or at Ser⁴⁷⁴ in Akt-2 (Meier et al., 1997). The enzyme responsible for phosphorylation of Ser⁴⁷³/Ser⁴⁷⁴ was originally named PDK-2 but recently the integrin-linked kinase, ILK (Delcommenne et al., 1998) has emerged as a candidate for this function.

Two human isoforms of Akt have been described to date, Akt-1 and Akt-2 (Coffey & Woodgett, 1991; Jones et al., 1991; Cheng et al., 1992). A third isoform, here referred to as Akt-3, has been described in the rat (Konishi et al., 1995). Since this rat Akt-3 possesses an apparently truncated tail and thereby lacks Ser⁴⁷³, its regulation may differ from that of Akt-1 and Akt-2. Both Akt-1 and Akt-2 are expressed widely, although the expression of Akt-2 is most prominent in insulin-responsive tissues, such as liver and skeletal muscle

(Konishi et al., 1994; Altomare et al., 1995). Akt-1 and Akt-2 are activated by insulin in rat adipocytes, hepatocytes and skeletal muscle. In contrast, Akt-3 does not appear to be strongly activated by insulin in these tissues (Walker et al., 1998). The role of the various Akt isoforms in insulin signalling may limit the utility of compounds that inhibit Akt-1 or Akt-2 activity as such agents may induce symptoms observed in patients with diabetes. We hypothesized that this problem may be avoided by using selective inhibitors of Akt-3 and this prompted us to identify the human analogue of rat Akt-3.

BRIEF DESCRIPTION OF THE FIGURES

The present invention may be more clearly understood with reference to the following example which is purely exemplary and the accompanying drawings wherein:

Figure 1 is an alignment of the deduced amino acid sequences for human Akt-1, Akt-2 and Akt-3. The sequences were aligned using the ClustalW alignment program (EMBL, Heidelberg, Germany). Amino acid residues conserved between all three proteins are included in the black areas. Residues conserved between only two of the sequences are shaded in grey. Amino acid residues are numbered in the right hand column. The conserved Thr and Ser residues that are presumed to be phosphorylated upon activation are marked with an asterisk above the sequence.

Figure 2 is an illustration of phosphorylation of histone H2B by Akt-3 variants. (A) Akt-3 was expressed as a GST fusion protein in *E. Coli*. To assess hAkt-3 activity, Histone H2B was incubated with GST-Akt-3 and GST-Akt-3 variants for the indicated time and the extent of phosphorylation assessed after SDS-PAGE. The

variants of Akt-3 are designated: W.T., wild type; T305D, Thr³⁰⁵ mutated to Asp; S472D, Ser⁴⁷² mutated to Asp; T305D,S472D, both Thr³⁰⁵ and Ser⁴⁷² mutated to Asp. No significant phosphorylation was observed when GST

5 was used in place of GST-Akt. The results are the mean (\pm s.e.m.; n = 3 to 6) and are expressed relative to the extent of phosphorylation of H2B catalysed by T305D, S472D hAkt-3 after 45 minutes. (B) HEK-293 cells were transfected with either vector (lanes 1 & 10 2) or Akt-3 (lanes 3 and 4) AKt-3T305A (lanes 5 & 6) or Akt-3 S472A (lanes 7 and 8) and either treated with buffer (lanes 1, 3 5 and 7) or IGF-1 (50 ng/ml; lanes 2, 4, 6 and 8). Akt-3 was immunoprecipitated with antibody 3F10 (anti-HA tag). Samples were analysed by 15 blotting for the HA-tag (upper panel) or with a phosphospecific antibody which recognises phosphorylated ser⁴⁷² (lower panel). (C) Akt activity in HA-immuno-precipitates from samples prepared as described above was assessed by measuring 20 phosphorylation of a peptide substrate (Crosstide). The results are expressed as the increase in activity compared to unstimulated cells transfected with empty vector (mean \pm s.e.m., n=7).

25 Figure 3 is an illustration of inhibition of Akt-3 by staurosporine and R0 31-8220. Histone H2B was treated with Akt-3 (T305D,S472D variant) in the presence of the indicated concentrations of either staurosporine or R0 31-8220. After 30 minutes, the reaction was 30 terminated and the extent of H2B phosphorylation quantified on a phosphorimager following SDS-PAGE. The results (mean \pm s.e.m., n=3) are expressed as relative to (%) the phosphorylation observed in the presence of solvent (control, "C").

35

Figure 4 is an illustration of chromosomal localisation of human Akt-3. Diagram of FISH mapping

results of Akt-3. Each dot represents the double FISH signals detected on human chromosome 1, region q43-q44.

5 Figure 5 is an illustration of expression of Akt-3 in different human tissues. (A) Northern blot analysis of tissue expression of Akt-3. The expression of hAkt-3 mRNA in different human tissues was assessed using a probe corresponding to the 3' untranslated region of
10 hAkt-3 to analyse a blot of human polyA⁺ RNA (AMultiple Tissue Northern[®]). Human β -actin was used as a control to confirm equal loading of the lanes (data not shown). (B) and (C) RT-PCR analysis of tissue expression of Akt-3. RT-PCR analyses were
15 performed on cDNA from different human tissues (B) and from different tumor cell lines (C) using primers specific for human Akt-3 or G3PDH (control) for the indicated number of PCR cycles. Bands of the expected size (425 bp for Akt-3 and 1 kb for G3PDH) are visible
20 on the gels. The images from the ethidium bromide stained 1.2% agarose gels were inverted for clarity using the EagleSight software (Stratagene). The results from similar PCR reactions performed for 25, 30 or 35 cycles are not shown but indicated that the
25 results from this figure are in the linear range of amplification. Caco-2 = colorectal adenocarcinoma; T-84 = colorectal carcinoma; MCF-7 = breast adenocarcinoma; T-47D = breast ductal gland carcinoma; HT1080 = bone fibrosarcoma; SaOS-2 = osteosarcoma; SK-
30 N-MC = neuroblastoma; HepG2 = hepatoblastoma; JURKAT = T-cell leukemia.

Figure 6 is an illustration of the results obtained by scintillation counting in a scintillation proximity
35 assay to identify agents that modulate the activity of Akt-3 activity.

Figure 7 is an illustration of the results obtained from an Akt-3 filter assay to identify agents that modulate activity of Akt-3.

5 DETAILED DESCRIPTION OF THE INVENTION

The present inventors have now identified and characterised a nucleic acid molecule that encodes the human isoform of Akt-3. Significantly, human Akt-3
10 possesses a COOH-terminal tail that contains an amino acid residue analogous to Ser⁴⁷³/Ser⁴⁷⁴ previously implicated in the activation of Akt-1/Akt-2, but absent in the rat Akt-3 protein.

15 Therefore, there is provided by a first aspect of the present invention a nucleic acid molecule encoding human Akt-3 or a functional equivalent, derivative or bioprecursor thereof, comprising the amino acid sequence illustrated in Figure 1 (and as SEQ ID NO:3).

20 Preferably, the molecule is a DNA molecule and even more preferably a cDNA molecule, and even more preferably comprises the sequence of nucleotides provided in SEQ ID NO:1. Also provided by this aspect
25 of the invention is a nucleic acid molecule capable of hybridising to the molecule according to the invention under high stringency conditions.

Stringency of hybridisation as used herein refers to
30 conditions under which polynucleic acids are stable. The stability of hybrids is reflected in the melting temperature (T_m) of the hybrids. T_m can be approximated by the formula:

35
$$81.5^{\circ}\text{C} + 16.6(\log_{10}[\text{Na}^+] + 0.41 (\% \text{G\&C}) - 600/l$$
 wherein l is the length of the hybrids in nucleotides.
 T_m decreases approximately by 1-1.5°C with every 1%

decrease in sequence homology.

The term "stringency" refers to the hybridisation conditions wherein a single-stranded nucleic acid joins with a complementary strand when the purine or pyrimidine bases therein pair with their corresponding base by hydrogen bonding. High stringency conditions favour homologous base pairing whereas low stringency conditions favour non-homologous base pairing.

10

"Low stringency" conditions comprise, for example, a temperature of about 37°C or less, a formamide concentration of less than about 50%, and a moderate to low salt (SSC) concentration; or, alternatively, a temperature of about 50°C or less, and a moderate to high salt (SSPE) concentration, for example 1M NaCl.

15

"High stringency" conditions comprise, for example, a temperature of about 42°C or less, a formamide concentration of less than about 20%, and a low salt (SSC) concentration; or, alternatively, a temperature of about 65°C, or less, and a low salt (SSPE) concentration. For example, high stringency conditions comprise hybridization in 0.5 M NaHPO₄, 7% sodium dodecyl sulfate (SDS), 1 mM EDTA at 65°C (Ausubel, F.M. et al. Current Protocols in Molecular Biology, Vol. I, 1989; Green Inc. New York, at 2.10.3).

25

"SSC" comprises a hybridization and wash solution. A stock 20X SSC solution contains 3M sodium chloride, 0.3M sodium citrate, pH 7.0.

30

"SSPE" comprises a hybridization and wash solution. A 1X SSPE solution contains 180 mM NaCl, 10mM NaH₂PO₄ and 1 mM EDTA, pH 7.4.

35

The nucleic acid capable of hybridising to nucleic acid molecules according to the invention will generally be at least 85%, preferably at least 90% and even more preferably at least 95% homologous to the
5 nucleotide sequences according to the invention.

The DNA molecules according to the invention may, advantageously, be included in a suitable expression vector to express polypeptides encoded therefrom in a
10 suitable host.

The present invention also comprises within its scope proteins or polypeptides encoded by the nucleic acid molecules according to the invention or a functional
15 equivalent, derivative or bioprecursor thereof.

An expression vector according to the invention includes a vector having a nucleic acid according to the invention operably linked to regulatory sequences,
20 such as promoter regions, that are capable of effecting expression of said DNA fragments. The term "operably linked" refers to a juxta position wherein the components described are in a relationship permitting them to function in their intended manner.
25 Such vectors may be transformed into a suitable host cell to provide for expression of a polypeptide according to the invention. Thus, in a further aspect, the invention provides a process for preparing polypeptides according to the invention which
30 comprises cultivating a host cell, transformed or transfected with an expression vector as described above under conditions to provide for expression by the vector of a coding sequence encoding the polypeptides, and recovering the expressed
35 polypeptides.

The vectors may be, for example, plasmid, virus or

phage vectors provided with an origin of replication, optionally a promoter for the expression of said nucleotide and optionally a regulator of the promoter. The vectors may contain one or more selectable
5 markers, such as, for example, ampicillin resistance.

Regulatory elements required for expression include promoter sequences to bind RNA polymerase and transcription initiation sequences for ribosome
10 binding. For example, a bacterial expression vector may include a promoter such as the lac promoter and for transcription initiation the Shine-Dalgarno sequence and the start codon AUG. Similarly, a eukaryotic expression vector may include a
15 heterologous or homologous promoter for RNA polymerase II, a downstream polyadenylation signal, the start codon AUG, and a termination codon for detachment of the ribosome. Such vectors may be obtained commercially or assembled from the sequences described
20 by methods well known in the art.

A nucleic acid molecule according to the invention may be inserted into the vectors described in an antisense orientation in order to provide for the production of
25 antisense RNA. Antisense RNA or other antisense nucleic acids may be produced by synthetic means.

In accordance with the present invention, a defined nucleic acid includes not only the identical nucleic
30 acid but also any minor base variations including in particular, substitutions in bases which result in a synonymous codon (a different codon specifying the same amino acid residue) due to the degenerate code in conservative amino acid substitutions. The term
35 "nucleic acid sequence" also includes the complementary sequence to any single stranded sequence given regarding base variations.

The present invention also advantageously provides nucleic acid sequences of at least approximately 10 contiguous nucleotides of a nucleic acid according to the invention and preferably from 10 to 120, and even more preferably from 10 to approximately 50 nucleotides. These sequences may, advantageously be used as probes or primers to initiate replication, or the like. Such nucleic acid sequences may be produced according to techniques well known in the art, such as by recombinant or synthetic means. They may also be used in diagnostic kits or the like for detecting the presence of a nucleic acid according to the invention. These tests generally comprise contacting the probe with the sample under hybridising conditions and detecting for the presence of any duplex or triplex formation between the probe and any nucleic acid in the sample.

According to the present invention these probes may be anchored to a solid support. Preferably, they are present on an array so that multiple probes can simultaneously hybridize to a single biological sample. The probes can be spotted onto the array or synthesised *in situ* on the array. (See Lockhart et al., Nature Biotechnology, vol. 14, December 1996 "Expression monitoring by hybridisation to high density oligonucleotide arrays"). A single array can contain more than 100, 500 or even 1,000 different probes in discrete locations.

Advantageously, the nucleic acid sequences, according to the invention may be produced using such recombinant or synthetic means, such as for example using PCR cloning mechanisms which generally involve making a pair of primers, which may be from approximately 10 to 50 nucleotides to a region of the

gene which is desired to be cloned, bringing the primers into contact with mRNA, cDNA, or genomic DNA from a human cell, performing a polymerase chain reaction under conditions which bring about

- 5 amplification of the desired region, isolating the amplified region or fragment and recovering the amplified DNA. Generally, such techniques as defined herein are well known in the art, such as described in Sambrook et al (Molecular Cloning: a Laboratory
10 Manual, 1989).

The nucleic acids or oligonucleotides according to the invention may carry a revealing label. Suitable labels include radioisotopes such as ^{32}P or ^{35}S , enzyme
15 labels or other protein labels such as biotin or fluorescent markers. Such labels may be added to the nucleic acids or oligonucleotides of the invention and may be detected using known techniques *per se*.

- 20 A further aspect of the invention comprises human Akt-3 or a functional equivalent, derivative or bioprecursor thereof, comprising an amino acid sequence as illustrated in Figure 1.

- 25 The polypeptide designated human Akt-3 according to the invention includes all possible amino acid variants encoded by the nucleic acid molecule according to the invention including a polypeptide encoded by said molecule and having conservative amino
30 acid changes. Polypeptides according to the invention further include variants of such sequences, including naturally occurring allelic variants which are substantially homologous to said polypeptides. In this context, substantial homology is regarded as a
35 sequence which has at least 90% amino acid homology with the polypeptides encoded by the nucleic acid molecules according to the invention and even more

preferably at least 95% amino acid homology.

The nucleic acid molecule or the human Akt-3 according to the invention may, advantageously, be used as a
5 medicament or in the preparation of a medicament, for treating disease associated with Akt-3 activity such as, cancer or the like.

Advantageously, the nucleic acid molecule or the
10 polypeptide according to the invention may be provided in a pharmaceutical composition together with a pharmaceutically acceptable carrier, diluent or excipient therefor.

15 The present invention is further directed to inhibiting Akt-3 *in vivo* by the use of antisense technology. Antisense technology can be used to control gene expression through triple-helix formation or antisense DNA or RNA, both of which methods are
20 based on binding of a polynucleotide to DNA or RNA. For example, the 5' coding portion of the mature protein sequence, which encodes for the protein of the present invention, is used to design an antisense RNA oligonucleotide of from 10 to 40 base pairs in length.
25 A DNA oligonucleotide is designed to be complementary to a region of the gene involved in transcription (triple-helix - see Lee et al. Nucl. Acids Res., 6:3073 (1979); Cooney et al., Science, 241:456 (1988); and Dervan et al., Science, 251: 1360 (1991), thereby
30 preventing transcription and the production of Akt-3. The antisense RNA oligonucleotide hybridises to the mRNA *in vivo* and blocks translation of an mRNA molecule into the Akt-3 (antisense - Okano, J. Neurochem., 56:560 (1991); Oligodeoxynucleotides as
35 Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1998)).

Alternatively, the oligonucleotide described above can be delivered to cells by procedures in the art such that the anti-sense RNA or DNA may be expressed in vivo to inhibit production of Akt-3 in the manner described above.

Antisense constructs to Akt-3, therefore, may inhibit the survival of the cell and prevent further cancer or tumour growth.

According to a further aspect of the invention there is also provided a transgenic cell, tissue or organism comprising a transgene capable of expressing human Akt-3 protein according to the invention. The term "transgene capable of expression" as used herein means a suitable nucleic acid sequence which leads to expression of human Akt-3 or human proteins having the same function and/or activity. The transgene, may include, for example, genomic nucleic acid isolated from human cells or synthetic nucleic acid, including DNA integrated into the genome or in an extrachromosomal state. Preferably, the transgene comprises the nucleic acid sequence encoding the proteins according to the invention as described herein, or a functional fragment of said nucleic acid. A functional fragment of said nucleic acid should be taken to mean a fragment of the gene comprising said nucleic acid coding for the proteins according to the invention or a functional equivalent, derivative or a non-functional derivative such as a dominant negative mutant, or bioprecursor of said proteins. For example, it would be readily apparent to persons skilled in the art that nucleotide substitutions or deletions may be used using routine techniques, which do not affect the protein sequence encoded by said nucleic acid, or which encode a functional protein according to the invention.

Human Akt-3 protein expressed by said transgenic cell,
tissue or organism or a functional equivalent or
bioprecursor of said protein also form part of the
5 present invention.

Antibodies to human Akt-3 may, advantageously, be
prepared by techniques which are known in the art. For
example, polyclonal antibodies may be prepared by
10 inoculating a host animal, such as a mouse, with human
Akt-3 according to the invention or an epitope thereof
and recovering immune serum. Monoclonal antibodies may
be prepared according to known techniques such as
described by Kohler R. and Milstein C., Nature (1975)
15 256, 495-497.

Antibodies according to the invention may also be used
in a method of detecting for the presence of human
Akt-3 according to the invention, which method
20 comprises reacting the antibody with a sample and
identifying any protein bound to said antibody. A kit
may also be provided for performing said method which
comprises an antibody according to the invention and
means for reacting the antibody with said sample.

25 Proteins which interact with the polypeptide of the
invention may be identified by, for example,
investigating protein-protein interactions using the
two-hybrid vector system first proposed by Chien et al
30 (1991). Proc. Natl. Acad. Sci. USA 88: 9578-9582.

This technique is based on functional reconstitution
in vivo of a transcription factor which activates a
reporter gene. More particularly the technique
35 comprises providing an appropriate host cell with a
DNA construct comprising a reporter gene under the
control of a promoter regulated by a transcription

factor having a DNA binding domain and an activating domain, expressing in the host cell a first hybrid DNA sequence encoding a first fusion of a fragment or all of a nucleic acid sequence according to the invention and either said DNA binding domain or said activating domain of the transcription factor, expressing in the host at least one second hybrid DNA sequence, such as a library or the like, encoding putative binding proteins to be investigated together with the DNA binding or activating domain of the transcription factor which is not incorporated in the first fusion; detecting any binding of the proteins to be investigated with a protein according to the invention by detecting for the presence of any reporter gene product in the host cell; optionally isolating second hybrid DNA sequences encoding the binding protein.

An example of such a technique utilises the GAL4 protein in yeast. GAL4 is a transcriptional activator of galactose metabolism in yeast and has a separate domain for binding to activators upstream of the galactose metabolising genes as well as a protein binding domain. Nucleotide vectors may be constructed, one of which comprises the nucleotide residues encoding the DNA binding domain of GAL4. These binding domain residues may be fused to a known protein encoding sequence, such as for example the nucleic acids according to the invention. The other vector comprises the residues encoding the protein binding domain of GAL4. These residues are fused to residues encoding a test protein. Any interaction between polypeptides encoded by the nucleic acid according to the invention and the protein to be tested leads to transcriptional activation of a reporter molecule in a GAL-4 transcription deficient yeast cell into which the vectors have been transformed. Preferably, a reporter molecule such as

β -galactosidase is activated upon restoration of transcription of the yeast galactose metabolism genes.

A further aspect of the invention provides a method of
5 identifying compounds which selectively inhibit human Akt-3 mediated promotion of cell survival said method comprising i) providing a cell transformed with an expression vector activating the Akt-3 pathway which cell survives in the presence or absence of a survival
10 factor compared to a control cell which has not been transformed with said vector and will die in the absence of said survival factor ii) contacting said cells with a test compound following removal of said cells from said survival factors, wherein death of
15 said transformed cell is indicative of selective inhibition of said compound on the survival promoting human Akt-3 pathway.

Alternatively, the survival promoting activity of Akt-
20 3 could be assessed by i) providing a cell transformed with an expression vector activating the Akt-3 pathway in addition to a control cell which has not been transformed with said vector, ii) contacting each of said cells with a death inducing agent, whereby death
25 of said control cell and survival of said transformed cell is indicative of the survival promoting activity of the activated Akt-3 pathway, iii) subsequently contacting said transformed cell without removal of said death inducing agent, with a test compound,
30 wherein death of said cell is indicative of selective inhibition of said compound on the survival promoting human Akt-3 pathway.

In a further aspect the present invention provides
35 methods to identify agents that affect the activity of the human Akt-3 protein, comprising contacting said protein with a substrate, regulatory molecule or

surrogate thereof and monitoring the interaction with the test substance using standard phosphorylation or binding assays well known in the art.

- 5 Compounds which are identified according to this aspect of the invention in addition to antibodies to the human Akt-3 may, advantageously, be utilised as a medicament or alternatively in the preparation of a medicament for treating diseases associated with
- 10 expression of human Akt-3 protein according to the invention.

- A further aspect of the invention provides a pharmaceutical composition comprising any of a
- 15 compound, an antisense molecule or an antibody according to the invention together with a pharmaceutically acceptable carrier, diluent or excipient therefor.
- 20 The antisense molecules or indeed the compounds identified as agonists or antagonists of the nucleic acids or polypeptides according to the invention may be used in the form of a pharmaceutical composition, which may be prepared according to procedures well
- 25 known in the art. Preferred compositions include a pharmaceutically acceptable vehicle or diluent or excipient, such as for example, a physiological saline solution. Other pharmaceutically acceptable carriers including other non-toxic salts, sterile water or the
- 30 like may also be used. A suitable buffer may also be present allowing the compositions to be lyophilized and stored in sterile conditions prior to reconstitution by the addition of sterile water for subsequent administration. Incorporation of the
- 35 polypeptides of the invention into a solid or semi-solid biologically compatible matrix may be carried out which can be implanted into tissues requiring

treatment.

The carrier can also contain other pharmaceutically acceptable excipients for modifying other conditions
5 such as pH, osmolarity, viscosity, sterility, lipophilicity, solubility or the like.

Pharmaceutically acceptable excipients which permit sustained or delayed release following administration
10 may also be included.

The polypeptides, the nucleic acid molecules or compounds according to the invention may be administered orally. In this embodiment they may be
15 encapsulated and combined with suitable carriers in solid dosage forms which would be well known to those skilled in the art.

As would be well known to those of skill in the art,
20 the specific dosage regime may be calculated according to the body surface area of the patient or the volume of body space to be occupied, dependent upon the particular route of administration to be used. The amount of the composition actually administered will,
25 however, be determined by a medical practitioner, based on the circumstances pertaining to the disorder to be treated, such as the severity of the symptoms, the composition to be administered, the age, weight, and response of the individual patient and the chosen
30 route of administration.

EXAMPLES

MATERIALS AND METHODS

35

Oligonucleotide synthesis and DNA sequence determination

All primers were obtained from Eurogentec, Seraing, Belgium. Insert-specific sequencing primers (15- and 16-mers) were designed by visual inspection of the DNA sequences. DNA was prepared on Qiagen-tip-20 columns or on Qiaquick spin columns (Qiagen GmbH, Düsseldorf, Germany) and recovered from the spin columns in 30 Fl Tris/EDTA-buffer (10mM TrisHCl pH 7.5, 1 mM EDTA (sodium salt)). Sequencing reactions were performed using BigDye™ Terminator Cycle Sequencing Ready Reaction kits (Perkin Elmer, ABI Division, Foster City, CA, USA) and were run on an Applied Biosystems 377 DNA sequencer (Perkin Elmer, ABI Division, Foster City, CA, USA).

15

Molecular cloning of human Akt-3.

Using the rat RAC-PK γ sequence (Konishi et al, 1995; GenBank acc. No. D49836) as a query sequence, a BLAST (Basic Local Alignment Search Tool; Altschul et al., 1990) search was carried out in the WashU Merck expressed sequence tag (EST) database (Lennon et al., 1996) and in the proprietary LifeSeq™ human EST database (Incyte Pharmaceuticals Inc, Palo Alto, CA, USA). Several human EST clones with high similarity to the rat RAC-PK γ were identified. One EST sequence (Incyte accession number 2573448) derived from a hippocampal cDNA library, contained part of the coding sequence including the putative methionine start codon (ATG) and part of the 5' untranslated region. The start codon was surrounded by a Kozak consensus sequence for translation start and an in-frame stop codon was present at positions -6 to -3. Based on this 239 bp sequence, oligonucleotide sense primers were synthesised for 3' rapid amplification of cDNA ends (3' RACE) experiments: Akt-3sp1 = 5'-ACC ATT TCT CCA AGT TGG GGG CTC AG-3' and Akt-3sp2 = 5'GGG AGT CAT CAT GAG CGA TGT TAC C-3'. 3'RACE experiments were performed on

human fetal brain or human cerebellum Marathon-Ready™ cDNA (Clontech Laboratories, Palo Alto, CA, USA) according to manufacturer's instructions using Akt-3sp1/race-ap1 as primers in the primary PCR and Akt-3sp2/race-ap2 in the nested PCR. Resulting PCR fragments were cloned and sequenced. This extended the Akt-3 coding sequence by 916 bp, but the novel sequence did not include an in-frame stop codon. A second round of 3' RACE amplification was performed on human brain Marathon Ready™ cDNA using sense primers based on the sequence obtained in the first round (Akt-3sp3 = 5' CAC TCC AGA ATA TCT GGC ACC AGA GG-3' and Akt-3sp4 = 5' CTA TGG CCG AGC AGT AGA CTG GTG G-3') in combination with race-ap1 and race-ap2, respectively. The sequence obtained included an in-frame stop codon and the 3' untranslated sequence up to the poly(A) tail. Antisense primers were designed based on the 3' untranslated region (Akt-3ap4 = 5'-TGC CCC TGC TAT GTG TAA GAG CTA GG-3' and Akt-3ap5 = 5' AAG AGC TAG GAC TGG TGA TGT CCA GG-3') and the complete Akt-3 coding sequence was amplified from human hippocampal cDNA using Akt-3sp1/Akt-3ap4 (primary PCR) and Akt-3sp2/Akt-3ap5 (nested PCR) as primers. The resulting 1200 bp PCR fragment was then cloned in the TA-cloning vector pCR2.1 (original TA cloning kit, Invitrogen BV, Leek, The Netherlands) and the inserts of several clones were completely sequenced. One clone containing an insert with the confirmed sequence (hAkt-3/pCR2.1) was used for subsequent subcloning to the mammalian expression vector pcDNA-3 (Invitrogen), yielding construct hAkt-3/pcDNA-3. In order to make a construct coding for a COOH-terminal tagged Akt-3 protein, a fragment of 553 bp was amplified from plasmid Akt-3/pcDNA-3 using an antisense primer incorporating a XhoI restriction site and the sequence coding for a hemagglutinin (HA) tag (YPYDVPDYA) after amino acid 479 of the Akt-3 sequence. This fragment

was recloned into plasmid hAkt-3/pcDNA-3 using *Bst*EII and *Xho*I restriction sites yielding construct HA-hAkt-3/pcDNA-3.

5 **Constructs and mutants for *E. coli* expression of Akt-3.**

In order to express the human Akt-3 protein in *E. coli*, the complete Akt-3 coding sequence was amplified from plasmid hAkt-3/pCR2.1 using primers introducing a *Eco*RI restriction site and a *Xho*I restriction site at the 5' and 3' ends, respectively. This PCR fragment was cloned as a *Eco*RI/*Xho*I fragment in vector pGEX-4T-3 (Amersham Pharmacia Biotech, Uppsala, Sweden) yielding construct hAKT-3(WT)/pGEX-4T-3, and the sequence of the insert was confirmed by sequence analysis.

15

Mutants of this construct were made using the Quickchange site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA) according to the manufacturer's instructions. The T305D mutant (construct hAKT-3(T305D)/pGEX-4T-3) was created by mutating ACA at position 923-925 to GAC, resulting in a Thr³⁰⁵ to Asp mutation in the resulting protein. The S472D mutant (construct hAKT-3(S472D)/pGEX-4T-3) was created by changing TC at position 1404-1405 to GA using PCR with a long antisense primer incorporating the change, resulting in a Ser⁴⁷² to Asp mutation in the resulting protein. A double mutant was also constructed by site-directed mutagenesis on hAKT-3(S472D)/pGEX-4T-3 and contained both these mutations (construct hAKT-3(T305D/S472D)/pGEX-4T-3). The inserts of all resulting constructs were confirmed by complete sequence analysis. The fusion proteins resulting from expression of these constructs in *E. coli* contain a GST moiety coupled to the NH₂-terminus of the human Akt-3 sequence.

35

Expression in Cos-7 cells and HEK-293 cells

Akt-3 was transiently expressed in Cos-7 by calcium phosphate transfection of the cells with the construct
5 HA-hAkt-3/pcDNA-3. The cells were stimulated with 10 ng/ml IGF-1 for 30 minutes, lysed and Akt-3 immunoprecipitated with mAb 12CA5. Akt-3 activity was assessed as described below.

- 10 For expression in HEK-293 cells, cells were transfected with pcDNA-3 Akt-3 constructs as described previously (Alessi et al 1996). After stimulation with IGF, the cells were lysed (Alessi et al 1996) and HA-Akt immunoprecipitated with antibody 3F10 (Roche
15 Molecular Biochemicals). Akt activity was assessed in immune complexes by measuring phosphorylation of a peptide substrate (Crosstide) in the presence of 1 μ M PKI (PKA inhibitor) and 1 μ M GF 109302X (PKC inhibitor) as described.

20

Expression and assay of wild-type and mutant Akt-3 in *E. coli*.

The pGEX expression constructs were transformed into *E. coli* strain BL21 DE3 and GST-fusion proteins of
25 wild-type and mutated Akt-3 were purified on glutathione sepharose according to the manufacturer's instructions (Amersham Pharmacia Biotech, Uppsala, Sweden). The protein eluted from the beads was stored in 50% glycerol at -20°C. Akt activity was assessed
30 by incubating 0.8 Fg of the purified enzyme for 30 minutes at room temperature (unless otherwise indicated) in a buffer containing 10 mM HEPES, 10 mM $MgCl_2$, 1 mM DTT, 0.1 mg/ml histone H2B at pH 7.0, in a total volume of 25 μ l and containing 10 FCi [γ - 32 P]-ATP
35 (6000 Ci/mmol). Initial experiments indicated that the reaction was linear with time for at least 45 minutes.

The reaction was stopped by the addition of 25 μ l sample buffer for SDS-PAGE. The results were quantified on a phosphorimager following SDS-PAGE on a 15% (w/v) acrylamide gel.

100250 0.009867

Chromosomal mapping studies

Chromosomal mapping studies were carried out by SeeDNA Biotech Inc, Toronto, Canada using fluorescent *in situ* hybridisation (FISH) analysis essentially as described (Heng et al., 1992; Heng & Tsui, 1993). Briefly, human lymphocytes were cultured at 37°C for 68-72 h before treatment with 0.18 mg/ml 5-bromo-2'-deoxyuridine (BrdU) to synchronize the cell cycle in the cell population. The synchronized cells were washed and recultured at 37°C for 6 h. Cells were harvested and slides were prepared using standard procedures including hypotonic treatment, fixation and air-drying. A cDNA probe for Akt-3 (1.44 kb *EcoRI* fragment of clone hAkt-3/pcDNA-3) was biotinylated and used for FISH detection. Slides were baked at 55°C for 1 h, treated with RNase and denatured in 70% (v/v) formamide in 2x NaCl/Cit (0.3 M NaCl, 0.03 M disodium citrate, pH 7.0) for 2 min at 70°C followed by dehydration in ethanol. Probes were denatured prior to loading on the denatured chromosomal slides. After overnight hybridisation, slides were washed and FISH signals and the 4',6-diamidino-2-phenylindole banding pattern were recorded separately on photographic film, and the assignment of the FISH mapping data with chromosomal bands was achieved by superimposition of FISH signals with 4,6-diamidino-2-phenylindole banded chromosomes (Heng & Tsui, 1993).

30 Northern blot analysis.

Northern blots containing 2 Fg of poly(A)-rich RNA derived from different human tissues (Clontech Laboratories, Palo Alto, CA, USA) were hybridised according to the manufacturer's instructions with a α -³²P-dCTP random-priming labelled (HighPrime kit, Boehringer Mannheim) 454 bp *NotI*-*XbaI* Akt-3 fragment (nucleotides 1404 to 1857) corresponding to part of

the 3' untranslated sequence.

Reverse transcription (RT)-PCR analysis

- Oligonucleotide primers were designed for the specific
5 PCR amplification of a fragment from Akt-3. These
primers were Akt-3sp2 = 5'-GGG AGT CAT CAT GAG CGA TGT
TAC C-3' (sense primer) and Akt-3ap1 = 5'- GGG TTG TAG
AGG CAT CCA TCT CTT CC -3' (antisense primer),
yielding a 425 bp product. PCR amplifications for
10 human glyceraldehyde-3-phosphate dehydrogenase (G3PDH)
were performed on the same cDNA samples as positive
controls using G3PDH primers 5'-TGA AGG TCG GAG TCA
ACG GAT TTG GT-3' (sense primer) and 5'-CAT GTG GGC CAT
GAG GTC CAC CAC-3' (antisense primer), yielding a 1000
15 bp fragment. These primers were used for PCR
amplifications on Multiple Tissue cDNA panels
(Clontech Laboratories) and on cDNA prepared from
tumor cell lines. For the preparation of tumor cell
cDNA, cells were homogenised and total RNA prepared
20 using the RNeasy Mini kit (Qiagen GmbH, Hilden,
Germany) according to manufacturer's instructions. 1
Fg of total RNA was reverse transcribed using
oligo(dT)₁₅ as a primer and 50 U of Expand™ Reverse
Transcriptase (Boehringer Mannheim, Mannheim, Germany)
25 according to the manufacturer's instructions. PCR
reactions with Akt-3-specific or G3PDH-specific
primers were then performed on 1 Fl of cDNA. Images of
the ethidium bromide stained gels were obtained using
the Eagle Eye II Video system (Stratagene, La Jolla,
30 CA, USA) and PCR bands analysed using the EagleSight
software.

Assays to identify agents that modulate the activity of Akt-3

- 35 To identify agents that modulate the activity of Akt-
3, SPA (scintillation proximity assay) and filter
assays for Akt-3 activity were developed.

SPA assays were performed at 25°C for 3 hrs in the presence of 25mM Hepes, pH 7.0, containing 15 mM MgCl₂, 1 mM DTT. Each assay was performed in a 100 F1 reaction volume containing 111nM GST-AKT-3 (diluted in 25 mM Hepes, pH 7.0, containing 15 mM MgCl₂, 1 mM DTT), 0.75 FM Biotinylated Histone H2B, 2nM [γ -³³P]-ATP and any agents under test. The reaction was terminated by addition of 100 F1 Stop mix (50 FM ATP, 5 mM EDTA, 0.1% BSA, 0.1% Triton X-100 and 7.5 mg/ml Streptavidin coated PVT SPA beads). After allowing the beads to settle for 30 minutes, the assay mixture was counted in a microtiterplate scintillation counter. The results are illustrated in Figure 6.

AKT3 filter assays were performed at 25°C for 3 hrs in the presence of 25mM Hepes, pH7.0, containing 15 mM MgCl₂, 1 mM DTT. Each assay was performed in a 100 F1 reaction volume containing 111 nM GST-AKT-3 (diluted in 25mM Hepes, pH7.0, containing 15 mM MgCl₂, 1 mM DTT), 2.5 FM Histone H2B, 2nM [γ -³³P]-ATP and any agents under test. The reaction was terminated by addition of 100 F1 75 mM H₃PO₄. 90F1 of the assay mixture was filtered through Phosphocellulose cation exchange paper. After five times washing with 75 FM H₃PO₄, the filterpaper was counted in a microtiterplate scintillation counter. The results are illustrated in Figure 8.

30 **RESULTS**

Molecular cloning of human Akt-3.

Similarity searching of the LifeSeq™ and EMBL databases using the rat Akt-3 sequence as a query sequence yielded several human EST sequences which encoded part of the human homologue of rat Akt-3. Using the DNA sequence information in the databases,

- we were able in subsequent 3' RACE experiments to deduce the complete cDNA sequence for the human Akt-3 (SEQ ID NO:1, coding DNA is provided as SEQ ID NO:2). The obtained cDNA sequence encoded a protein of 479 amino acid residues (SEQ ID NO:3) with a calculated molecular mass of 55770 Da. The first 451 amino acids of the human Akt-3 protein contain only two differences to the corresponding rat sequence (Konishi et al., 1995) - Asp (rat) to Gly (human) at position 10 and Pro (rat) to Ala (human) at position 396 and encode a pleckstrin homology domain, a kinase domain and a COOH-terminal "tail". The two amino acid residues that are presumed to be phosphorylated upon activation of Akt-3 (Thr³⁰⁵ and Ser⁴⁷²) are in bold and marked with an asterisk. The COOH-terminal part of the human Akt-3 protein that differs with the rat homologue extends from amino acid 452 through amino acid 479.
- The predicted Akt-3 (Figure1) protein shows significant similarity with Akt-1 (Jones et al, 1991; 83.6% identity; 87.8% similarity) and with Akt-2 (Cheng et al., 1992; 78% identity; 84.3% similarity). The COOH-terminal "tail" has been observed in both human and rat Akt-1 and Akt-2 proteins, but it is apparently truncated in the only other reported Akt-3 sequence (rat Akt-3, Konishi et al., 1995; accession number D49836). 3'RACE experiments performed on human cDNAs derived from different tissues did not yield evidence for the existence of a shorter form of Akt-3 that would be analogous to the rat Akt-3 (data not shown). The tail in human Akt-3 comprises 28 amino acid residues (YDEGDMDCMDNERRPHFPQFSYSASGRE) that replace 3 amino acid residues in the rat sequence (CPL). The tail in human Akt-3 contains a serine residue at position 472 (shown in bold) that corresponds to Ser⁴⁷³ in Akt-1 or

Ser⁴⁷⁴ in Akt-2. Phosphorylation of Ser⁴⁷³ and Ser⁴⁷⁴ has previously been implicated in the activation of Akt-1 and Akt-2, respectively (Alessi et al., 1996; Meier et al., 1997). Thr³⁰⁸ (in the kinase domain) has
5 also been implicated in the activation of Akt-1 and this residue is also conserved in human Akt-3 (Thr³⁰⁵).

Characterisation of Akt-3 activity.

To characterise the enzymatic activity of Akt-3, we
10 expressed and purified the recombinant enzyme as a GST fusion protein. Analysis of the purified product by SDS-PAGE indicated the protein was apparently > 90% pure. The purified enzyme was able to phosphorylate histone H2B (Figure 2), and no phosphorylation was
15 observed using recombinant GST alone. Previously, the enzymatic activity of Akt-1 has been shown to be increased by phosphorylation of Thr³⁰⁸ and Ser⁴⁷³, and mutation of both these residues to Asp (to mimic phosphorylation) synergistically activates Akt-1
20 (Alessi et al., 1996). To investigate whether Akt-3 is similarly regulated, GST-fusion proteins in which either Thr³⁰⁵ or Ser⁴⁷² (corresponding to Thr³⁰⁸ and Ser⁴⁷³ in Akt-1) or both Thr³⁰⁵ and Ser⁴⁷² had been mutated to Asp were expressed and assayed in comparison to the
25 wild-type enzyme. Mutation of Thr³⁰⁵ to Asp ("T305D") resulted in a 2.0-fold increase in the initial rate of phosphorylation of histone H2B, whereas mutation of Ser⁴⁷² to Asp (S472D) increased the initial rate only 1.4 fold (Figure 2A). When both Thr³⁰⁵ and Ser⁴⁷²
30 ("T305D,S472D) were mutated to Asp, a 3.2-fold increase in the initial phosphorylation rate was observed.

To confirm that extracellular stimuli can activate
35 Akt-3 in mammalian cells, Cos-7 cells were transfected with a cDNA encoding Akt-3 fused to a HA tag. Akt-3 activity in HA immunoprecipitates was increased 1.5

and 1.9 fold (n=2) following stimulation with IGF-1 (10 ng/ml).

To further confirm that extracellular stimuli can
5 activate Akt-3 in mammalian cells, HEK-293 cells were
transfected with a cDNA encoding Akt-3 fused to a HA
epitope tag. Upon treatment with IGF, Akt-3 activity
in anti-HA immunoprecipitates (Figure 2B) was
increased almost 60-fold above that in untransfected
10 cells (Figure 2C). Akt variants in which Thr³⁰⁵ and
Ser⁴⁷² were mutated to alanine were refractory to
activation by IGF. Consistent with this, Western
blotting with a Ser⁴⁷² phosphospecific antibody of HA
immunoprecipitates from cells stimulated with IGF
15 demonstrated that Ser⁴⁷² was phosphorylated following
stimulation with IGF (Figure 2B). In addition,
activation of Akt-3 was inhibited by prior treatment
with CY29 4002 (100 FM, 94% inhibition), data not
shown).

20 To characterise human Akt-3 further, we investigated
the ability of a range of Ser/Thr kinase inhibitors to
inhibit Akt-3. These included Go 6976, GF-109203X
(both protein kinase C (PKC) inhibitors); H-85, H-88,
25 H-89 and KT5720 (protein kinase A (PKA) inhibitors),
KN-62 (Ca²⁺/Calmodulin dependent kinase inhibitor) and
PD 98059 (MEK inhibitor). When tested at a
concentration of 10 FM these compounds had no
significant effect on the activity of the T305D,S472D
30 variant of Akt-3. However, the broad spectrum kinase
inhibitor staurosporine (IC₅₀ = 2.0 ± 0.3 FM) and the
PKC inhibitor Ro 31-8220 (IC₅₀ = 3.2 ± 1.0 FM) inhibited
the T305D,S472D variant of Akt-3 (Figure 4).

Chromosomal localisation of Akt-3.

The complete coding sequence of Akt-3 was used as a probe for FISH analysis. Under the conditions used, the hybridisation efficiency was approximately 75% for this probe (among 100 checked mitotic figures, 75 of them showed signals on one pair of the chromosomes). Since the DAPI-banding was used to identify the specific chromosome, the assignment between the signal from the probe and the long arm of chromosome 1 was obtained. The detailed position was further determined in the diagram based upon the summary from 10 photographs (Figure 4). There was no additional locus picked by FISH detection under the conditions used, therefore, it was concluded that Akt-3 is located at human chromosome 1, region q43-q44. FISH signals were localized to chromosome 1 on the samples tested. The mitotic figures stained with 4',6- diamidino-2-phenylindole to identify chromosome 1.

Tissue distribution of Akt-3 mRNA.

Northern blot analysis was performed on mRNA derived from different human tissues. Akt-3 mRNA was detected as two transcripts of approximately 4.5 kb and 7.5 kb, showing similar patterns of expression (Fig. 6A). Akt-3 mRNA was expressed in a range of tissues, most prominently in brain. Similarly, rat Akt-3 was detected as multiple transcripts most highly expressed in brain (Konishi et al., 1995). The weakest expression of Akt-3 was observed in two insulin-responsive tissues, skeletal muscle and liver. Akt-3 was also expressed in a number of cancer cell lines including SW480 colorectal adenocarcinoma, A549 lung carcinoma and G361 Melanoma (data not shown).

To confirm the Northern blot analysis, PCR reactions were performed with Akt-3 specific and G3PDH-specific

(internal control) primers on cDNAs derived from different human tissues (Fig. 6B). The Akt-3 message was present in every tissue tested, since a specific 425 bp fragment was amplified in every cDNA after 30 cycles of PCR. Akt-3 mRNA expression was high in placenta, ovary and spleen. Moderate expression was seen in brain, heart, kidney, colon, prostate, small intestine and testis. Lowest expression was in liver, lung, pancreas, skeletal muscle, peripheral blood leukocytes and thymus. In tumor cell lines (Figure 5C), Akt-3 mRNA expression was relatively high in HT-1080 bone fibrosarcoma cells, in SaOS-2 osteosarcoma and in JURKAT T-cell leukemia cells (Akt-3 band detectable after 30 cycles of PCR). Caco-2 colorectal adenocarcinoma, T84 colorectal carcinoma, MCF-7 breast adenocarcinoma and SK-N-MC neuroblastoma cells show Akt-3 mRNA expression after 35 cycles of PCR. In T-47D breast ductal gland carcinoma and HepG2 hepatoblastoma, expression of Akt-3 mRNA is very low or absent (no signal detectable after 35 cycles of PCR).

Akt-1 and Akt-2 have been identified in several species. Human (Jones et al., 1991; Coffey et al 1991), mouse (Bellacosa et al., 1993) and bovine (Coffey & Woodgett, 1991) Akt-1 clones have been reported, whereas human (Cheng et al., 1992) mouse (Altomare et al., 1995) and rat (Konishi et al., 1994) clones of Akt-2 have been identified. However, Akt-3 has only been previously identified in rat (Konishi et al, 1995). The present inventors have identified the human isoform of Akt-3. Although human Akt-3 shows considerable similarity to human Akt-1 and Akt-2, the discovery of human Akt-3 is particularly significant because the cDNA sequence encodes a COOH-terminal Atail₃ which includes a phosphorylation site implicated in the activation of Akt-1 and Akt-2 (Alessi et al., 1996; Meier et al., 1997). This tail

is absent from the predicted rat amino acid sequence. Human Akt-3 appears to be activated by phosphorylation in a similar fashion as Akt-1 and Akt-2. However, its expression profile suggests that the principal
5 function of this enzyme is not in regulating responses to insulin.

The sequence which has been identified represents the human homologue of Akt-3. This assignment is based on
10 the >99% identity between the rat and human Akt-3 protein sequences. With the exception of the COOH-terminal tail seen in human Akt-3, there are only 2 amino acid differences (Gly¹⁰ and Ala³⁹⁶ in human Akt-3) between the rat and human Akt-3 proteins. Alignment of
15 all the previously described Akt sequences demonstrates that Gly¹⁰ and Ala³⁹⁶ in the human protein correspond to Gly and Ala residues respectively in the Akt-1 and Akt-2 sequences identified from other
20 species. Further evidence that we have identified the Akt-3 isoform comes from the presence of isotype-specific sequences represented by human Akt-3 residues 47-49 (LPY), 118-122 (NCSPT) and 139-141 (HHK). For each isotype, these sequences are conserved between
species, but differ between the isotypes.

25 The human Akt-3 cDNA sequence was predicted to encode a NH₂-terminal pleckstrin homology (PH) domain (Musacchio et al., 1993) and a COOH-terminal kinase domain. A striking difference between the human and
30 rat Akt-3 protein sequence (Konishi, et al., 1995) is the presence of a COOH-terminal Atail₃ comprising 74 residues after the kinase domain. The last 28 amino acid residues in human Akt-3 are absent from the rat Akt-3 sequence. We were unable to identify human cDNA
35 sequences that encoded a similar truncation, despite conducting RACE experiments using cDNA from several different human tissues. The region in human Akt-3

- that is absent from rat Akt-3 encompasses a stretch of 10 residues (residues 467-476 in human Akt-3) which are identical to the corresponding region of human Akt-1 and Akt-2. This suggests that the tail observed in human Akt-3 is authentic. The significance of the difference observed in the rat Akt-3 tail region remains to be investigated. However, the human Akt-3 COOH-terminal sequence includes Ser⁴⁷², which corresponds to Ser⁴⁷³ in Akt-1. Phosphorylation of Ser⁴⁷³ has been shown to lead to a 5-fold increase in the activity of Akt-1, whereas a 20-25 fold increase of Akt-1 activity is observed if both Ser⁴⁷³ and Thr³⁰⁸ are phosphorylated (Alessi et al., 1996). Thus, our observation that Ser⁴⁷² is present in human Akt-3 is significant, because it suggests that human Akt-3 is potentially regulated in a manner similar to Akt-1 and Akt-2. Whether rat Akt-3 is regulated in a different fashion remains to be resolved.
- The kinase and PH domains in Akt-3 show homology to the consensus PH and kinase domain sequences (Musacchio et al., 1993; Hanks & Hunter 1995). The PH domain of human Akt-3 is 77% and 86% identical to the PH domains in Akt-1 and Akt-2, respectively, while the kinase domain of Akt-3 is 88% and 87% identical to the kinase domain of Akt-1 and Akt-2, respectively. The high conservation of the PH domain may indicate an Akt-specific function, because PH domains are often highly divergent (Musacchio et al, 1993). Apart from binding phosphoinositides, the PH domain of Akt has been shown to mediate interactions between Akt and PKC (Konishi, et al., 1995) as well as directing the formation of multimeric Akt complexes (Datta et al, 1995). In contrast, the region between the PH domain and the kinase domain is poorly conserved between the human Akt-1, Akt-2 and Akt-3 sequences, and this region is also important for mediating the formation

of multimeric Akt complexes (Datta et al, 1995). This raises an interesting issue - whether the sequence NH₂-terminal to the kinase domain of Akt-3 mediates the interaction with binding partners that are unique to Akt-3 or that bind to multiple Akt isoforms.

To verify that the predicted kinase domain was catalytically active, we expressed Akt-3 as a GST fusion protein in *E. coli*. The purified protein was able to phosphorylate an exogenous substrate, whereas no catalytic activity was observed using GST in place of GST-Akt-3. To confirm that Akt-3 is indeed regulated in a manner akin to Akt-1 and Akt-2, we mutated Thr³⁰⁵ and Ser⁴⁷³, either separately or jointly, to Asp. This strategy has previously been shown to faithfully mimic the effect of phosphorylation of these residues in Akt-1 (Alessi et al., 1996). Mutation of either of these residues resulted in increased activity, although the increase was less than that observed with Akt-1 (Alessi et al., 1996). Additionally, we did not observe a synergistic activation of Akt-3 by mutation of both Thr³⁰⁵ and Ser⁴⁷³. In contrast, when both the corresponding residues were simultaneously mutated to Asp in Akt-1, synergistic activation was observed (Alessi et al, 1996). The apparent quantitative differences between Akt-1 and Akt-3 may reflect true differences in the regulation of these two isoforms, or it may be due to other factors such as the different expression system used. In the present study Akt-3 was expressed as a GST fusion protein in *E. coli*, whereas Akt-1 activity was studied using an HA-tagged protein expressed in COS cells. Nevertheless, our results demonstrate that Akt-3 is qualitatively regulated in a fashion similar to Akt-1. Previous work has also shown that activation of Akt is dependent upon PI 3-kinase to generate 3-phosphoinositides that bind the PH domain of Akt,

promote translocation of Akt to the plasma membrane and facilitate the phosphorylation of Akt by upstream kinases (reviewed in Alessi & Cohen, 1998; Coffey et al., 1998). Our observation that the T305D/S472D mutant of Akt-3 is more active than the wild type enzyme (Figure 2), when measured in the absence of 3-phosphoinositides, suggests that after phosphorylation Akt-3 becomes (at least partially) independent of phosphoinositide binding.

The structure of the catalytic domain of Akt is closely related to protein kinase A and protein kinase C. Indeed, a BLAST search of the SwissProt data base revealed that the most closely related kinases (other than the different Akt isoforms) include several protein kinase C isozymes. This prompted us to investigate whether existing inhibitors of PKA or PKC, as well as other serine/threonine kinase inhibitors, could be used as inhibitors of Akt-3. Of the compounds tested, only staurosporine and the structurally related compound Ro 31-8220 both potently inhibited Akt-3. Staurosporine is a non-selective kinase inhibitor, whereas Ro 31-8220 is a more selective PKC inhibitor (Davis, et al., 1992). Although Ro 31-8220 is an approximately 100-fold more potent (IC_{50} 10 nM; Davis, et al., 1992) inhibitor of PKC than of Akt-3, this observation cautions that experiments using high concentrations of Ro 31-8220 may affect Akt-3. In contrast to staurosporine and Ro 31-8220, two other PKC inhibitors and three other PKA inhibitors did not inhibit Akt-3. This suggests that although Akt-3 is closely related in sequence to PKC, it may be possible to find selective inhibitors of Akt.

The observation that Akt-3 is activated by IGF-1 suggests that Akt-3 may play a role in regulating cell survival. Akt-3 potentially may suppress apoptosis in

tumor cells. One concern in using Akt as a target for drug development in cancer is that Akt plays a role in insulin signalling (reviewed in Sheperd et al, 1998). Thus, inhibitors of Akt may induce symptoms observed in patients with diabetes. One solution that has been proposed is to develop selective inhibitors of Akt-2 (Walker et al, 1998). This is based in part on the observation that Akt-1 is strongly activated by insulin in rat hepatocytes and skeletal muscle, whereas Akt-2 is only weakly activated by insulin in these tissues. However, rat Akt-3 appears to be even more weakly activated by insulin in these tissues (Walker et al, 1998), and in this study we have shown that Akt-3 mRNA is expressed only at low levels in human liver and skeletal muscle, which are insulin responsive tissues. This suggests that selective inhibitors of Akt-3 could have even less potential to cause symptoms similar to those seen in patients with diabetes than do inhibitors of Akt-2. The localisation of human Akt-3 to human chromosome 1q43-44 is also interesting, as patients with haematological cancers have been reported with chromosomal abnormalities in this region (Mitelman et al, 1997). Although the significance of the latter observation is debatable, as chromosomal abnormalities at numerous loci have been observed in patients with haematological cancers, the results presented here indicate that Akt-3 may prove to be an important target for the development of novel therapeutics for the treatment of cancer.

30

SEQUENCE LISTING

1. Sequence ID No. 1 corresponds to the nucleotide sequence of Akt-3.
- 5 2. Sequence ID No. 2 corresponds to from nucleotide position 11 to 1447 of the nucleic acid sequence of Akt-3.
- 10 3. Sequence ID No. 3 corresponds to the amino acid sequence of Akt-3 illustrated in Figure 1.

REFERENCES

- Ahmed, N.N, Grimes, H.L., Bellacosa, A., Chan, T.O.,
Tsichlis (1997) Transduction of interleukin-2
5 antiapoptotic and proliferative signals via Akt
protein kinase. *Proc. Natl Acad Sci USA* 94, 3627-3632.
- Alessi, D.R. & Cohen, P. (1998) Mechanism of
activation and function of protein kinase B. *Current*
10 *Opinion Gen. Dev.* 8, 55-62.
- Alessi, D.R., Andjelkovic, M., Caudwell, F.B., Cron,
P. Morrice, N., Cohen, P. & Hemmings, B. (1996)
Mechanism of activation of protein kinase B by insulin
15 and IGF1. *EMBO J.* 15, 6541-6551.
- Alessi, D.R., Deak, M., Casamayor, A., Caudwell, F.B.,
Morrice, N., Norma, D.G., Gaffney, P., Reese, C.B.,
MacDougall, C.N., Harbison, D., Ashworth, A. & Bownes,
20 M. (1997) 3-phosphoinositide-dependent protein kinase-
1 (PDK-1): structural and functional homology with the
Drosophila DSTP61 kinase. *Curr. Biol.* 7:776-789.
- Altomare, D.A., Guo, K, Cheng, J.Q., Sonoda, G.,
25 Walsh, K. & Testa, J.R., (1995) Cloning, chromosomal
localisation and expression analysis of the mouse Akt2
oncogene. *Oncogene* 11, 1055-1060.
- Altschul, S.F., Gish, W., Miller, W., Myers, E.W. &
30 Lipman, D.J. (1990). Basic local alignment search
tool, *J. Mol. Biol.* 215, 403-410.
- Bellacosa, A., Franke, T.F., Gonzalez-Portal, M.E.,
Detta, K., Taguchi, T., Gardner, J., Cheng, J.Q.,
35 Testa, J.R. & Tsichlis, P.N. (1993) structure,
expression and chromosomal mapping of c-akt:
relationship to v-akt and its implications. *Oncogene*

8, 745-754.

- Bellacosa, A., De Feo, D., Godwin, A.K., Bell, D.W.,
Cheng, J.Q., Altomare, D.A., Wan, M., Dubeau, L.,
5 Scambia, G., Masciullo, V., Ferrandina, G., Benedetti
Panicini, P., Mancuso, S., Neri, G. & Testa, J.R.
(1995) Molecular alterations of the Akt2 oncogene in
ovarian and breast cancer, *Int. J. Cancer* 64, 280-285.
- 10 Cheng, J.Q., Godwin, A.K., Bellacosa, A., Taguchi, T.,
Franke, T.F., Hamilton, T.C., Tschlis, P.N. & Testa,
J.R. (1992) AKT2, a putative oncogene encoding a
member of a subfamily of protein-serine/threonine
kinases, is amplified in human ovarian carcinomas.
15 *Proc. Natl. Acad. Sci. USA* 89, 9267-9271.
- Coffer, P.J. & Woodgett, J.R. (1991) Molecular cloning
and characterisation of a novel putative protein-
serine kinase related to the cAMP-dependent and
20 protein kinase C. families. *Eur. J. Biochem.* 201,
475-481.
- Coffer, P.J., Jin, J. & Woodgett, J.R. (1998) Protein
kinase B (c-Akt) - A multifunctional mediator of
25 phosphatidylinositol 3-kinase activation. *Biochem J.*
335:1-13.
- Cohen, P., Alessi, D.R. & Cross, D.A.E. (1997) PDK1,
the missing link in insulin signal transduction? *FEBS*
30 *Lett.* 410, 3-10.
- Crowder, R.J. & Freeman, R.S. (1998)
Phosphatidylinositol 3-kinase and Akt protein kinase
are necessary and sufficient for the survival of nerve
35 growth factor-dependent sympathetic neurons, *J.*
Neurosci. 18, 2933-2943.

- Datta, S.R., Dudek, H., Tao, X., Masters, S., Fu, H.A., Gotoh, Y. & Greenberg, M.E. (1997) Akt Phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. *Cell* 91, 231-241.
- 5 Davis, P.D., Elliot L.H., Harris, W., Hill, C.H., Hurst, S.A., Keech, E., Kumar, M.K., Lawton, G., Nixon, J.S. & Wilkinson, W.E. (1992) Inhibitors of protein kinase C. 2. Substituted bisindolymaleimides with improved potency and selectivity. *J. Med. Chem.* 35, 994-1001.
- 10 del Peso, L., Gonzalez-Garcia, M., Page, C., Herrera, R., Nunez, G., (1997) Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. *Science* 278, 687-689.
- 15 Delcommenne, M., Tan, C., Gray, V., Rue, L. Woodgett, J. & Dedhar, S. (1998) Phosphoinositide-3-OH kinase-dependent regulation of glycogen synthase kinase 3 and protein kinase B/AKT by the intergrin-linked kinase. *Proc. Natl. Acad. Sci. USA* 95, 11211-11216.
- 20 Dudek, H., Datta, S.R., Franke, T.F., Bimbarun, M.J., Yao, R., Cooper, G.M., Segal, R.A., Kaplan, D.R. & Greenberg, M.E. (1997) Regulation of neuronal survival by the serine-threonine protein kinase Akt. *Science* 275, 661-665.
- 30 Eves, E.M., Xiong, W., Bellacosa, A., Kennedy, S.G., Tsichlis, P.N., Rosner, M.R. & Hay, N. (1998) Akt, a target of phosphatidylinositol 3-kinase, inhibits apoptosis in a differentiating neuronal cell line. *Mol. Cell. Biol.* 18, 2143-2152.
- 35 Frisch S.M. & Francis, H. (1994) Disruption of epithelial cell-matrix interactions induces apoptosis. *J. Cell. Biol.* 124, 619-626.

- Frisch, S.M. & Ruoslahti, E. (1997) Integrins and Anoikis. *Curr. Op. Cell. Biol.* 9, 701-706.
- 5 Hanks, S.K. & Hunter, T. (1995) The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification *FASEB J.* 9, 576-596.
- Hemmings, B.A. (1997) Akt signaling: linking membrane events to life and death decisions. *Science* 275, 628-630.
- 10 Heng, H.H.Q. & Tsui, L.-C. (1993) Modes of DAPI banding and simultaneous *in situ* hybridization. *Chromosoma* 102, 325-332.
- 15 Heng, H.H.Q., Squire, J. & Tsui, L.-C. (1992) High resolution mapping of mammalian genes by *in situ* hybridization to free chromatin. *Proc. Natl. Acad. Sci. USA* 89, 9509-9513.
- 20 Jones, P.F., Jakubowicz, T., Pitossi, F.J., Maurer, F. & Hemmings, B.A. (1991) Molecular cloning and identification of a serine/threonine protein kinase of the second-messenger subfamily. *Proc. Natl. Acad. Sci. USA* 88, 4171-4175.
- 25 Kauffmann-Zeh, A., Rodriguez-Viciana P., Ulrich, E., Gilbert, C., Coffey, P., Downward, J. & Evan, G. (1997) Suppression of c-Myc-induced apoptosis by ras signalling through PI(3)K and PKB. *Nature* 385, 544-548.
- 30 Kennedy, S.G., Wagner, A.J., Conen, S.D., Jordan, J., Bellacosa, A., Tsichlis, A.N. & Hay, N. (1997) The PI 3-kinase/Akt signalling pathway delivers an anti-apoptotic signal. *Genes & Development* 11, 701-713.
- 35

Khawaja, A., Rodriquez-Viciana, P. Wennstrom, S.,
Warne, P.H. & Downward, J. (1997) Matrix adhesion and
ras transformation both activate a phosphoinositide 3-
5 OH kinase and protein kinase B/Akt cellular survival
pathway. *EMBO J.* 16, 2783-2793.

Konishi, H., Shinomura, T., Kuroda, S., Ono, Y. &
Kikkawa, U. (1994) Molecular Cloning of rat RAC
10 protein kinase α and β and their association with
protein kinase C ζ . *Biochem. Biophys. Res. Commun.* 205,
817-825.

Konishi, H., Kuroda, S., Tanaka, M., Matsuzaki, H.,
15 Ono, Y., Kameyama, K., Haga, T. & Kikkawa, U. (1995)
Molecular cloning and characterisation of a new member
of the RAC protein kinase family: association of the
pleckstrin homology domain of three types of RAC
protein kinase with protein kinase C subspecies and $\beta\gamma$
20 subunits of G proteins. *Biochem. Biophys. Res. Commun.*
216, 526-534.

Kulik, G., Klippel, A. & Weber, M.J. (1997) Anti-
apoptotic signalling by the insulin-like growth factor
25 receptor, phosphatidylinositol-3 kinase and Akt. *Mol.*
Cell. Biol. 17, 1595-1606.

Lennon, G., Auffray, C., Polymeropoulos, M. & Soares,
M.B. (1996) The I.M.A.G.E. Consortium: an integrated
30 molecular analysis of genomes and their expression.
Genomics 33, 151-152.

Marte, B.M. & Downward, J. (1997) PKB/Akt: connecting
phosphoinositide 3-kinase to cell survival and beyond.
35 *Trends Biochem. Sci.* 22, 355-358.

Marte, B.M., Rodriquez-Viciana, P., Wennstrom, S.,

- Warne, P.H. & Downward, J. (1997) R-Ras can activate the phosphoinositide 3-kinase but not the MAP kinase arm of the Ras effector pathways (1997) *Curr. Biol.* 7, 63-70.
- 5 Meier, R., Alessi, D.R., Cron, P., Andjelkovic, M. & Hemmings, B.A. (1997) Mitogenic activation, phosphorylation and nuclear translocation of protein kinase β . *J. Biol. Chem.* 272, 30491-30497.
- 10 Meredith J.E. Jr., Fazeli, B. & Schwartz, M.A. (1993) The extracellular matrix as a survival factor, *Mol. Cell Biol* 4, 953-961.
- 15 Mitelman, F., Mertens F. & Johansson, B., (1997) A breakpoint map of recurrent chromosomal rearrangements in human neoplasia, *Nature Genetics* 15, 417-474.
- 20 Musacchio, A., Gibson, T., Rice, P., Thompson, J. & Saraste, M. (1993) The PH domain: a common piece in the structural patchwork of signalling proteins. *Trends Biochem. Sci* 18, 343-348.
- Philpott, K.L., McCarthy, M.J., Klippel, A. & Rubin, L.L. (1997) Activated phosphatidylinositol 3-kinase and Akt kinase promote survival of superior cervical neurons. *J. Cell. Biol.* 139, 809-815.
- 30 Sheperd, P.R., Withers, D.J. & Siddle, K. (1998) Phosphoinositide 3-kinase: the key switch mechanism in insulin signalling. *Biochem J.* 333, 471-490.
- Stephens, L., Anderson, K., Stokoe, D., Erdjumentbromage, H., Painter, G.F., Homes, A.B., Gaffney, P.R.J., Reese, C.B., McCormick, F., Tempst, P., Coadwell, J. & Hawkins, P.T. (1998) Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent activation of protein kinase

B. *Science*, 279, 710-714.

- Staal, S.P. (1987) Molecular cloning of the *akt* oncogene and its human homologues AKT1 and AKT2:
5 amplification of AKT1 in a primary human gastric adenocarcinoma. *Proc. Natl. Acad Sci. USA* 89, 9267-9271.
- Stokoe, D., Stephens, L.R., Copeland, T., Gaffney,
10 P.R.J., Reese, C.B. & Painter, G.F. (1997) Dual role of phosphatidylinositol-3,4,5-triphosphate in the activation of protein kinase B. *Science* 277, 567-570.
- Walker, K.S., Deak, M., Paterson, A., Hudson, K.,
15 Cohen, P. & Alessi, D.R. (1998) Activation of protein kinase β and γ isoforms by insulin *in vivo* and by 3-phosphoinositide-dependent protein kinase-1 *in vitro*: comparison with protein kinase B α . *Biochem. J.* 331, 299-308.

SEQUENCE LISTING

<110> Masure, Stefan
Richardson, Alan

<120> Human AKT-3

<130> 51869/001

<140> PCT/GB99/04311

<141> 1999-12-17

<150> GB 9828375.7

<151> 1998-12-22

<160> 3

<170> PatentIn Ver. 2.0

<210> 1

<211> 1547

<212> DNA

<213> Homo sapiens

<400> 1

gggagtcacg atgagcgaag ttaccattgt gaaagaaggt tgggttcaga agaggggaga
60

atatataaaa aactggagggc caagatactt ccttttgaag acagatggct cattcatagg
120

atataaagag aaacctcaag atgtggattt accttatccc ctcaacaact tttagtgagg
180

aaaatgccag ttaatgaaaa cagaacgacc aaagccaaac acatttataa tcagatgtct
240

ccagtggaact actgttatag agagaacatt tcatgtatag actccagagg aaaggaaga
 300
 atggacagaa gctatccagg ctgtacaga cagactgcag aggaagaag aggagagaat
 360
 gaattgtagt ccaacttcac aaattgataa tataggagag gaagagatgg atgcctctac
 420
 aacctcatc aaaagaaaa caatgaatga ttttgactat ttgaaactac taggtaagg
 480
 cacttttggg aaagtatttt tggttcgaga gaaggcaagt ggaaataact atgctatgaa
 540
 gattctgaag aaagaagtca ttattgcaaa ggatgaagtg gcacacactc taactgaaag
 600
 cagagtatta aagaacacta gacatccctt ttaacatcc ttgaaatatt ccttcacagc
 660
 aaaagaccgt ttgtgttttg tgatggaata tgttaattgg ggcgagctgt ttttccattt
 720
 gtcgagagag cgggtgttct ctgaggacgg cacacgttcc tatggtgcag aaattgtctc
 780
 tgccttggac tatctacatt ccggaaagat tgtgtaccgt gatctcaagt tggagaatct
 840
 aatgctggac aaagatggcc acataaaaat tacagatttt ggactttgca aagaagggat
 900
 cacagatgca gccaccatga agacattctg tggcactcca gaatatctgg caccagaggt
 960
 gttagaagat aatgactatg gccgagcagt agactggtgg ggcctagggg ttgtcatgta
 1020
 tgaaatgatg tgtgggaggt tacctttcta caaccaggac catgagaaac tttttgaatt
 1080
 aatattaatg gaagacatta aatttcctcg aacactctct tcagatgcaa aatcattgct
 1140
 ttcagggtcc ttgataaagg atccaaaata acgccttggg ggaggaccag atgatgcaaa
 1200
 agaaattatg agacacagtt tcttctctgg agtaaaactgg caagatgtat atgataaaaa
 1260
 gcttgtagct ccttttaaac ctcaagtaac atctgagaca gatactagat attttgatga
 1320
 agaatttaca gctcagacta ttacaataac accacctgaa aaatatgatg aggatggtat
 1380
 ggactgcagt gacaatgaga ggcgccgca tttccctcaa ttttctact ctgcaagtgg
 1440
 acgagaataa gtctctttca ttctgtact tcactgtcat cttcaattta ttactgaaaa
 1500

tgattcctgg acatcaccag tcctagctct tacacatagc aggggca
1547

<210> 2

<211> 1435

<212> DNA

<213> Homo sapiens

<400> 2

atgagcgtg ttaccattgt gaaagaaggt tgggttcaga agaggggaga atatataaaa
60
aactggaggc caagatactt ccttttgaag acagatggct cattcatagg atataaagag
120
aaacctcaag atgtggattt accttatccc ctcaacaact tttcagtggc aaaatgccag
180
ttaatgaaaa cagaacgacc aaagccaaac acatttataa tcagatgtct ccagtggaact
240
actgttatag agagaacatt tcatgtagat actccagagg aaaggaaga atggacagaa
300
gctatccagg ctgtagcaga cagactgcag aggcaagaag aggagagaat gaattgtagt
360
ccaacttcac aaattgataa tataggagag gaagagatgg atgcctctac aacctatcat
420
aaaagaaaga caatgaatga ttttgactat ttgaaactac taggtaaagg cacttttggg
480
aaagttattt tgggttcgaga gaaggcaagt ggaaaatact atgctatgaa gattctgaag
540
aaagaagtca ttattgcaaa ggatgaagtg gcacacactc taactgaaag cagagtatta
600
aagaacacta gacatccctt ttaaacatcc ttgaaatatt ccttcagac aaaagaccgt
660
ttgtgttttg tgatggaata tgttaatggg ggcgagctgt tttccattt gtcgagagag
720
cgggtgttct ctgaggaccg cacacgtttc tatggtgcag aaattgtctc tgccctggac
780
tatctacatt ccgaaagat tgtgtaccgt gatctcaagt tggagaatct aatgctggac
840
aaagatggcc acataaaaaa tacagatttt ggactttgca aagaagggat cacagatgca
900

gccaccatga agacattctg tggcactcca gaatatctgg caccagaggt gttagaagat
960

aatgactatg gccgagcagt agactggtgg ggcttagggg ttgtcatgta tgaaatgatg
1020

tgtgggaggt tacctttcta caaccaggac catgagaaac tttttgaatt aatattaatg
1080

gaagacatta aatttcctcg aacactctct tcagatgcaa aatcattgct ttcagggctc
1140

ttgataaagg atccaaataa acgccttggt ggaggaccag atgatgcaaa agaaattatg
1200

agacacagtt tcttctctgg agtaaactgg caagatgtat atgataaaaa gcttgtacct
1260

cotttttaac ctcaagtaac atctgagaca gatactagat attttgatga agaatttaca
1320

gctcagacta ttacaataac accacctgaa aaatatgatg aggatgggtat ggactgcatg
1380

gacaatgaga ggcgggcgca tttccctcaa ttttctact ctgcaagtga acgaga
1436

<210> 3

<211> 479

<212> PRT

<213> Homo sapiens

<400> 3

Met Ser Asp Val Thr Ile Val Lys Glu Gly Trp Val Gln Lys Arg Gly

1

5

10

15

Glu Tyr Ile Lys Asn Trp Arg Pro Arg Tyr Phe Leu Leu Lys Thr Asp

20

25

30

Gly Ser Phe Ile Gly Tyr Lys Glu Lys Pro Gln Asp Val Asp Leu Pro

35

40

45

Tyr Pro Leu Asn Asn Phe Ser Val Ala Lys Cys Gln Leu Met Lys Thr

50	55	60
Glu Arg Pro Lys Pro Asn Thr Phe Ile Ile Arg Cys Leu Gln Trp Thr		
65	70	75 80
Thr Val Ile Glu Arg Thr Phe His Val Asp Thr Pro Glu Glu Arg Glu		
85	90	95
Glu Trp Thr Glu Ala Ile Gln Ala Val Ala Asp Arg Leu Gln Arg Gln		
100	105	110
Glu Glu Glu Arg Met Asn Cys Ser Pro Thr Ser Gln Ile Asp Asn Ile		
115	120	125
Gly Glu Glu Glu Met Asp Ala Ser Thr Thr His His Lys Arg Lys Thr		
130	135	140
Met Asn Asp Phe Asp Tyr Leu Lys Leu Leu Gly Lys Gly Thr Phe Gly		
145	150	155 160
Lys Val Ile Leu Val Arg Glu Lys Ala Ser Gly Lys Tyr Tyr Ala Met		
165	170	175
Lys Ile Leu Lys Lys Glu Val Ile Ile Ala Lys Asp Glu Val Ala His		
180	185	190
Thr Leu Thr Glu Ser Arg Val Leu Lys Asn Thr Arg His Pro Phe Leu		
195	200	205
Thr Ser Leu Lys Tyr Ser Phe Gln Thr Lys Asp Arg Leu Cys Phe Val		
210	215	220

10051-20386

Met Glu Tyr Val Asn Gly Gly Glu Leu Phe Phe His Leu Ser Arg Glu
 225 230 235 240

Arg Val Phe Ser Glu Asp Arg Thr Arg Phe Tyr Gly Ala Glu Ile Val
 245 250 255

Ser Ala Leu Asp Tyr Leu His Ser Gly Lys Ile Val Tyr Arg Asp Leu
 260 265 270

Lys Leu Glu Asn Leu Met Leu Asp Lys Asp Gly His Ile Lys Ile Thr
 275 280 285

Asp Phe Gly Leu Cys Lys Glu Gly Ile Thr Asp Ala Ala Thr Met Lys
 290 295 300

Thr Phe Cys Gly Thr Pro Glu Tyr Leu Ala Pro Glu Val Leu Glu Asp
 305 310 315 320

Asn Asp Tyr Gly Arg Ala Val Asp Trp Trp Gly Leu Gly Val Val Met
 325 330 335

Tyr Glu Met Met Cys Gly Arg Leu Pro Phe Tyr Asn Gln Asp His Glu
 340 345 350

Lys Leu Phe Glu Leu Ile Leu Met Glu Asp Ile Lys Phe Pro Arg Thr
 355 360 365

Leu Ser Ser Asp Ala Lys Ser Leu Leu Ser Gly Leu Leu Ile Lys Asp
 370 375 380

385 390 395 400

405 410 415

420 425 430

435 440 445

450 455 460

465 470 475

CLAIMS

1. A nucleic acid molecule encoding human Akt-3 protein or a functional equivalent, derivative or bioprecursor thereof, comprising the amino acid sequence illustrated in SEQ ID No. 3.
2. A nucleic acid molecule according to claim 1 which is a DNA molecule, and preferably cDNA.
3. A nucleic acid molecule according to claim 1 or 2 comprising the nucleotide sequence illustrated in SEQ ID No. 1.
4. A nucleic acid molecule according to claim 1 or 2 comprising the nucleotide sequence in SEQ ID No. 2.
5. An antisense molecule capable of hybridising to the molecule according to any of claims 1 to 4 under high stringency conditions.
6. A human Akt-3 protein or a functional equivalent, derivative or bioprecursor thereof, comprising an amino acid sequence as illustrated in SEQ ID No. 3.
7. A human Akt-3 protein or a functional equivalent, derivative or bioprecursor thereof encoded by a nucleic acid molecule according to any of claims 1 to 4.
8. A human Akt-3 protein according to claim 7 comprising the amino acid sequence as illustrated in SEQ ID No. 3.
9. An expression vector comprising a nucleic acid molecule according to claim 2 or 3.

10. An expression vector according to claim 9 comprising an inducible promoter.
11. An expression vector according to claim 9 or 10
5 comprising a sequence encoding a reporter molecule.
12. A nucleic acid molecule according to any of claims 1 to 5 for use as a medicament.
- 10 13. Use of a nucleic acid molecule according to any of claims 1 to 5 in the preparation of a medicament for treating cancer.
14. A human Akt-3 protein according to any of claims
15 6 to 8 for use as a medicament.
15. Use of a human Akt-3 protein according to any of claims 6 to 8 in the preparation of a medicament for treating cancer.
- 20 16. A pharmaceutical composition comprising a nucleic acid molecule according to any of claims 1 to 5 or a human Akt-3 protein according to any of claims 6 to 8 together with a pharmaceutically acceptable carrier
25 diluent or excipient therefor.
17. A host cell or organism, transformed or transfected with an expression vector according to any of claims 9 to 11.
- 30 18. A transgenic cell, tissue or organism comprising a transgene capable of expressing a human Akt-3 protein according to any of claims 6 to 8.
- 35 19. A human Akt-3 protein expressed from the cell or organism according to claim 17 or 18.

20. An antibody capable of binding to a human Akt-3 protein or an epitope thereof according to any of claims 6 to 8.

5 21. An antibody according to claim 20 which is a monoclonal antibody.

22. An antibody according to claim 20 or 21 for use as a medicament.

10

23. Use of an antibody according to claim 20 or 21 in the preparation of a medicament for treating cancer, or other diseases or conditions associated with human Akt-3 protein expression.

15

24. A kit for detecting human Akt-3 protein in a sample which protein comprises a sequence according to any of claims 6 to 8, said kit comprising an antibody according to claim 20 or 21 and means for contacting
20 said antibody with said sample.

25. A method of identifying compounds which selectively inhibit human Akt-3 protein mediated promotion of cell survival said method comprising:

25

i) providing a cell transformed with an expression vector activating the Akt-3 pathway that survives in the presence or absence of a survival factor compared to a control cell which has not been transformed with said vector and will die in the absence of said survival factor,

30

ii) contacting each of said cells with a test compound following the removal of said cells from said survival factor, wherein death of said transformed cell is indicative of selective inhibition of said compound on the survival promoting human Akt-3 pathway.
35

26. A method of identifying compounds which selectively inhibit human Akt-3 protein mediated promotion of cell survival, said method comprising:

- 5 i) providing a cell transformed with an expression vector activating the Akt-3 pathway in addition to a control cell which has not been transformed with said vector,
- 10 ii) contacting each of said cells with a death inducing agent, whereby death of said control cell and survival of said transformed cell is indicative of the survival promoting activity of the activated Akt-3 pathway,
- 15 iii) contacting said transformed cell with a test compound, wherein death of said cell is indicative of selective inhibition of said compound on the survival promoting human Akt-3 pathway.

20 27. A compound identifiable according to the method of claims 25 or 26.

28. A compound according to claim 27 for use as a medicament.

25

29. Use of a compound according to claim 27 in the manufacture of a medicament for treating diseases associated with human Akt-3 protein expression.

30 30. A method of identifying agents which influence the activity of a human Akt-3 protein according to any of claims 6 to 8, said method comprising contacting said human Akt-3 protein with a substrate therefor in the presence of a test compound and a phosphate
35 source, and monitoring for any phosphorylation of said substrate.

31. A method according to claim 30 wherein said Akt-3 protein is provided as a fusion or epitope tagged protein having a domain capable of phosphorylating a known substrate.
- 5 32. A method according to claim 30 wherein said Akt-3 protein is provided as a fusion molecule of GST and human Akt-3.
- 10 33. A method of identifying agents which influence the activity of a human Akt-3 protein according to any of claims 6 to 8, said method comprising contacting a phospholipid or a surrogate or functional equivalent thereof, with a PH domain of a human Akt-3 protein
- 15 according to any of claims 6 to 8 in the presence of an agent to be tested and monitoring for any binding of said phospholipid, surrogate or functional equivalent thereof with said PH domain of said Akt-3 protein.
- 20 34. A method according to claim 33 wherein said phospholipid comprises phosphatidylinositol 3,4,5-triphosphate.
- 25 35. An agent identifiable according to the method of claim 33 or 34.
- 30 36. An agent according to claim 35 for use as a medicament.
37. Use of an agent according to claim 35 in the preparation of a medicament for treating diseases associated with human Akt-3 expression.
- 35 38. A method of treating diseases associated with human Akt-3 activity said method comprising administering to an individual suffering from said

disease a compound that inhibits the function and/or expression of a human Akt-3 protein according to any of claims 6 to 8, in a sufficient concentration to reduce the symptoms of said disease.

5

39. A method according to claim 38 wherein said compound is any of an antisense molecule according to claim 5, an antibody according to claim 21 or 22, a compound according to claim 27 or an agent according to claim 35.

10

40. A method for making a pharmaceutical formulation for the treatment of diseases associated with human Akt-3 protein expression, said method comprising:

15

- a) contacting candidate compounds with a host cell that expresses human Akt-3 protein,
- b) selecting a compound identified in step a) which binds to human Akt-3 protein,
- c) manufacturing bulk quantities of the compound selected in step b), and
- d) formulating the compound manufactured in step c) in a pharmaceutically acceptable carrier.

20

41. A method of identifying a compound which modulates Akt-3 kinase activity, comprising:

30

- a) contacting said Akt-3 with a substrate thereof in the presence of a radiolabelled phosphate source, and the compound to be tested,
- b) stopping the reaction by the addition of kinase inhibitor in the presence of SPA beads,
- c) monitoring the signal from said beads compared to a control which has not been contacted with said compound.

35

42. A method of identifying a compound which modulates Akt-3 activity, comprising:

- 5 a) contacting said Akt-3 with a substrate thereof in the presence of a radiolabelled phosphate source, and the compound to be tested,
- b) stopping the reaction,
- c) filtering the reaction mixture through phosphocellulose cation exchange paper, and
- 10 d) monitoring the signal from said filter paper compared to a control which has not been contacted with said compound.

ABSTRACT

HUMAN AKT-3

- 5 There is disclosed a nucleic acid molecule encoding human Akt-3 protein or a functional equivalent or bioprecursor thereof comprising the amino acid sequence illustrated in Sequence ID No. 3. The human Akt-3 protein itself also forms part of the invention.
- 10 The nucleic acid molecule and the human Akt-3 protein may themselves be used as medicaments, or in the preparation of medicaments for treating cancer, in their own right or in the form of a pharmaceutically acceptable carrier, diluent or excipient thereof.
- 15 Further disclosed are methods of identifying agents which influence the activity of a human Akt-3 protein.

[illegible][illegible][illegible]

Akt-1	WYXDRERENMLDKHKKITDSCGKSGS	358
Akt-2	DVYIKLENNMLDKHKKITDSCGSGS	359
Akt-3	QVYIKLENNMLDKHKKITDSCGSGS	360
Akt-4	KVYIKLENNMLDKHKKITDSCGSGS	361
Akt-5	QVYIKLENNMLDKHKKITDSCGSGS	362
Akt-6	QVYIKLENNMLDKHKKITDSCGSGS	363
Akt-7	QVYIKLENNMLDKHKKITDSCGSGS	364
Akt-8	QVYIKLENNMLDKHKKITDSCGSGS	365
Akt-9	QVYIKLENNMLDKHKKITDSCGSGS	366
Akt-10	QVYIKLENNMLDKHKKITDSCGSGS	367
Akt-11	QVYIKLENNMLDKHKKITDSCGSGS	368
Akt-12	QVYIKLENNMLDKHKKITDSCGSGS	369
Akt-13	QVYIKLENNMLDKHKKITDSCGSGS	370
Akt-14	QVYIKLENNMLDKHKKITDSCGSGS	371
Akt-15	QVYIKLENNMLDKHKKITDSCGSGS	372
Akt-16	QVYIKLENNMLDKHKKITDSCGSGS	373
Akt-17	QVYIKLENNMLDKHKKITDSCGSGS	374
Akt-18	QVYIKLENNMLDKHKKITDSCGSGS	375
Akt-19	QVYIKLENNMLDKHKKITDSCGSGS	376
Akt-20	QVYIKLENNMLDKHKKITDSCGSGS	377
Akt-21	QVYIKLENNMLDKHKKITDSCGSGS	378
Akt-22	QVYIKLENNMLDKHKKITDSCGSGS	379
Akt-23	QVYIKLENNMLDKHKKITDSCGSGS	380
Akt-24	QVYIKLENNMLDKHKKITDSCGSGS	381
Akt-25	QVYIKLENNMLDKHKKITDSCGSGS	382
Akt-26	QVYIKLENNMLDKHKKITDSCGSGS	383
Akt-27	QVYIKLENNMLDKHKKITDSCGSGS	384
Akt-28	QVYIKLENNMLDKHKKITDSCGSGS	385
Akt-29	QVYIKLENNMLDKHKKITDSCGSGS	386
Akt-30	QVYIKLENNMLDKHKKITDSCGSGS	387
Akt-31	QVYIKLENNMLDKHKKITDSCGSGS	388
Akt-32	QVYIKLENNMLDKHKKITDSCGSGS	389
Akt-33	QVYIKLENNMLDKHKKITDSCGSGS	390
Akt-34	QVYIKLENNMLDKHKKITDSCGSGS	391
Akt-35	QVYIKLENNMLDKHKKITDSCGSGS	392
Akt-36	QVYIKLENNMLDKHKKITDSCGSGS	393
Akt-37	QVYIKLENNMLDKHKKITDSCGSGS	394
Akt-38	QVYIKLENNMLDKHKKITDSCGSGS	395
Akt-39	QVYIKLENNMLDKHKKITDSCGSGS	396
Akt-40	QVYIKLENNMLDKHKKITDSCGSGS	397
Akt-41	QVYIKLENNMLDKHKKITDSCGSGS	398
Akt-42	QVYIKLENNMLDKHKKITDSCGSGS	399
Akt-43	QVYIKLENNMLDKHKKITDSCGSGS	400
Akt-44	QVYIKLENNMLDKHKKITDSCGSGS	401
Akt-45	QVYIKLENNMLDKHKKITDSCGSGS	402
Akt-46	QVYIKLENNMLDKHKKITDSCGSGS	403
Akt-47	QVYIKLENNMLDKHKKITDSCGSGS	404
Akt-48	QVYIKLENNMLDKHKKITDSCGSGS	405
Akt-49	QVYIKLENNMLDKHKKITDSCGSGS	406
Akt-50	QVYIKLENNMLDKHKKITDSCGSGS	407
Akt-51	QVYIKLENNMLDKHKKITDSCGSGS	408
Akt-52	QVYIKLENNMLDKHKKITDSCGSGS	409
Akt-53	QVYIKLENNMLDKHKKITDSCGSGS	410
Akt-54	QVYIKLENNMLDKHKKITDSCGSGS	411
Akt-55	QVYIKLENNMLDKHKKITDSCGSGS	412
Akt-56	QVYIKLENNMLDKHKKITDSCGSGS	413
Akt-57	QVYIKLENNMLDKHKKITDSCGSGS	414
Akt-58	QVYIKLENNMLDKHKKITDSCGSGS	415
Akt-59	QVYIKLENNMLDKHKKITDSCGSGS	416
Akt-60	QVYIKLENNMLDKHKKITDSCGSGS	417
Akt-61	QVYIKLENNMLDKHKKITDSCGSGS	418
Akt-62	QVYIKLENNMLDKHKKITDSCGSGS	419
Akt-63	QVYIKLENNMLDKHKKITDSCGSGS	420
Akt-64	QVYIKLENNMLDKHKKITDSCGSGS	421
Akt-65	QVYIKLENNMLDKHKKITDSCGSGS	422
Akt-66	QVYIKLENNMLDKHKKITDSCGSGS	423
Akt-67	QVYIKLENNMLDKHKKITDSCGSGS	424
Akt-68	QVYIKLENNMLDKHKKITDSCGSGS	425
Akt-69	QVYIKLENNMLDKHKKITDSCGSGS	426
Akt-70	QVYIKLENNMLDKHKKITDSCGSGS	427
Akt-71	QVYIKLENNMLDKHKKITDSCGSGS	428
Akt-72	QVYIKLENNMLDKHKKITDSCGSGS	429
Akt-73	QVYIKLENNMLDKHKKITDSCGSGS	430
Akt-74	QVYIKLENNMLDKHKKITDSCGSGS	431
Akt-75	QVYIKLENNMLDKHKKITDSCGSGS	432
Akt-76	QVYIKLENNMLDKHKKITDSCGSGS	433
Akt-77	QVYIKLENNMLDKHKKITDSCGSGS	434
Akt-78	QVYIKLENNMLDKHKKITDSCGSGS	435
Akt-79	QVYIKLENNMLDKHKKITDSCGSGS	436
Akt-80	QVYIKLENNMLDKHKKITDSCGSGS	437
Akt-81	QVYIKLENNMLDKHKKITDSCGSGS	438
Akt-82	QVYIKLENNMLDKHKKITDSCGSGS	439
Akt-83	QVYIKLENNMLDKHKKITDSCGSGS	440
Akt-84	QVYIKLENNMLDKHKKITDSCGSGS	441
Akt-85	QVYIKLENNMLDKHKKITDSCGSGS	442
Akt-86	QVYIKLE	




AKT-1	ELIIMETIPFATILPEAKSILGALLKNDKPSALGGSSEDAKSEHCHPFAHCHWCHBENKKEBEPFQVWSEBDRVPBEPFACU	448
AKT-2	ELIIMETIPFATILPEAKSILGALLKNDKPSALGGSSEDAKSEHCHPFAHCHWCHBENKKEBEPFQVWSEBDRVPBEPFACU	449
AKT-3	ELIIMETIPFATILPEAKSILGALLKNDKPSALGGSSEDAKSEHCHPFAHCHWCHBENKKEBEPFQVWSEBDRVPBEPFACU	445
AKT-4	ELIIMETIPFATILPEAKSILGALLKNDKPSALGGSSEDAKSEHCHPFAHCHWCHBENKKEBEPFQVWSEBDRVPBEPFACU	445
AKT-5	ELIIMETIPFATILPEAKSILGALLKNDKPSALGGSSEDAKSEHCHPFAHCHWCHBENKKEBEPFQVWSEBDRVPBEPFACU	445

```

Akt-1 : ITTPTDQDS--MEQVDSERREHFFQFYSASSTA : 480
Akt-2 : ITTPTDQDS--LGLLEDCSTHFFQFYSASIRE : 481
Akt-3 : ITTPEKDEQDQDMDNERRREHFFQFYSASRE : 479

```

FIGURE 1

A**B****C****Figure 2**





Figure 3



Figure 4

09869079-00000000




Figure 5




Figure 5B





Figure 5C

**Figure 6**




Figure 7

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : MASURE et al.

Serial No. : Art Unit:

Filed : June 20, 2001 Examiner:

For : HUMAN AKT-3

Commissioner for Patents
Washington, D.C. 20231


ASSOCIATE POWER OF ATTORNEY

Sir:

In the matter of the above-identified application, I hereby appoint Myra H. McCormack (Reg. No. 36,602), whose postal address is One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933-7003, my associate attorney to prosecute said application, to make alterations and amendments therein, to file continuing applications claiming the benefit of said application, to receive the patent and to transact all business in the Patent Office connected with said application.

I request all communications with respect to said application be addressed to Philip S. Johnson, One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933-7003. All telephone calls should be directed to Myra H. McCormack at (732) 524-6932.

Signed at New Brunswick, in the County of Middlesex and State of New Jersey, this 20th day of June, 2001.


Mary A. Appollina
Reg. No. 34,087
Attorney for Applicant(s)

One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-2797

DATED: June 20, 2001

Please type a plus sign (+) inside this box → ☐

PTO/SB/01 (12-97)

Approved for use through 9/30/00. OMB 0651-0032

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

DECLARATION FOR UTILITY OR DESIGN PATENT APPLICATION (37 CFR 1.63)

☒ Declaration Submitted with Initial Filing **OR** ☐ Declaration Submitted after Initial Filing (surcharge (37 CFR 1.16 (e)) required)

Attorney Docket Number		JAB 1458 -PCT-USA	
First Named Inventor		Masure, Stefan L.J.	
COMPLETE IF KNOWN			
Application Number		/	
Filing Date			
Group Art Unit			
Examiner Name			

As a below named inventor, I hereby declare that:

My residence, post office address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

HUMAN AKT-3

the specification of which

☐ is attached hereto
OR

☒ was filed on (MM/DD/YYYY) 12/17/1999 as United States Application Number or PCT International

Application Number PCT/GB99/04311 and was amended on (MM/DD/YYYY) (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YYYY)	Priority Not Claimed	Certified Copy Attached? YES NO
9826375.7 /	GB /	12/22/1998 /	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>	<input type="checkbox"/> <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>

☐ Additional foreign application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto:

I hereby claim the benefit under 35 U.S.C. 119(e) of any United States provisional application(s) listed below.

Application Number(s)	Filing Date (MM/DD/YYYY)	<input type="checkbox"/> Additional provisional application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.

[Page 1 of 3]

Burden Hour Statement: This form is estimated to take 0.4 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO, Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/01 (12-97)
Approved for use through 9/30/00. OMB 0651-0032
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

DECLARATION — Utility or Design Patent Application

I hereby claim the benefit under 35 U.S.C. 120 of any United States application(s), or 35(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of 35 U.S.C. 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent Application or PCT Parent Number	Parent Filing Date (MM/DD/YYYY)	Parent Patent Number (if applicable)

☐ Additional U.S. or PCT international application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.

As a named inventor, I hereby appoint the following registered practitioner(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

☐ Customer Number → Place Customer Number Bar Code Label here
OR
☒ Registered practitioner(s) name/registration number listed below

Name	Registration Number	Name	Registration Number
Steven P. Berman	24,772	Michael Stark	32,495
Andrea L. Colby	30,194	Ellen C. Coletti	34,140
		Mary A. Apollina	34,087

☐ Additional registered practitioner(s) named on supplemental Registered Practitioner Information sheet PTO/SB/02C attached hereto.

Direct all correspondence to: ☐ Customer Number OR ☒ Correspondence address below or Bar Code Label

Name	Philip S. Johnson		
Address	Johnson & Johnson		
Address	One Johnson & Johnson Plaza		
City	New Brunswick	State	NJ
ZIP	08933-7003		
Country	USA	Telephone	(732) 524-2359
Fax	(732) 524-2808		

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Name of Sole or First Inventor: ☐ A petition has been filed for this unsigned inventor

Given Name (first and middle if any)	Family Name or Surname
Stefan Leo Jozef	Masure

Inventor's Signature	<u>Masure</u>			Date	5 April '01
Residence: City	B-2930 Brasschaat	State	Bex	Country	Belgium
Post Office Address	c/o Janssen Pharmaceutica N.V., Turnhoutseweg 30				
Post Office Address					
City	Beerse	State		ZIP	2340
Country	Belgium				

☒ Additional inventors are being named on the 1 supplemental Additional Inventor(s) sheet(s) PTO/SB/02A attached hereto

Please type a plus sign (+) inside this box → ☐

PTO/SB/02A (3-97)
Approved for use through 9/30/98. OMB 0651-0032
Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

DECLARATION

ADDITIONAL INVENTOR(S)
Supplemental Sheet
Page 3 of 3

Name of Additional Joint Inventor, if any:

☐ A petition has been filed for this unsigned inventor

Given Name (first and middle [if any])

Family Name or Surname

Alan

Richardson

Inventor's
Signature

Date

April 5, 2001

Residence: City

B-2460 Kasterlee

BEX
State

Country

Belgium

Citizenship

Great
Britain

Post Office Address

c/o Janssen Pharmaceutica N.V., Turnhoutseweg 30

Post Office Address

City

Beerse

State

ZIP

2340

Country

Belgium

Name of Additional Joint Inventor, if any:

☐ A petition has been filed for this unsigned inventor

Given Name (first and middle [if any])

Family Name or Surname

Inventor's
Signature

Date

Residence: City

State

Country

Citizenship

Post Office Address

Post Office Address

City

State

ZIP

Country

Name of Additional Joint Inventor, if any:

☐ A petition has been filed for this unsigned inventor

Given Name (first and middle [if any])

Family Name or Surname

Inventor's
Signature

Date

Residence: City

State

Country

Citizenship

Post Office Address

Post Office Address

City

State

ZIP

Country

Burden Hour Statement: This form is estimated to take 0.4 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.